ICG Enterprise Trust plc
Unaudited Interim Results for the six months ended 31 July 2026
7 October 2026

     
  Highlights

  • Six-month period demonstrating growth across multiple investment areas, positive net Portfolio cashflow and selective investment
  • NAV per Share of 2,091p at 31 July 2026. HY NAV per Share Total Return of 3.3% and 5-year annualised return of 8.4%
  • Portfolio Return on a Sterling Basis of 3.6% over the six months, driven by Directs
  • Portfolio reporting LTM revenue growth of 11% and EBITDA growth of 16%1
  • Total Proceeds of £84m, of which £32m came from exits of two of our top 30 companies (Curium, Yudo). A further ~£70m of proceeds expected to be received in coming quarters from two further large exits (Exail, Ambassador Theatre Group)
  • 24 Full Exits at a weighted-average Multiple of Cost of 3.0x and Uplift to Carrying Value of 9.4%
  • Continuing to invest selectively: Total New Investments of £65m and New Fund Commitments of £104m
  • £20m buybacks executed in H1, increasing NAV per Share by 14.9p (0.7%). Q2 dividend of 9.5p per share; Board intention remains to pay total FY27 dividends of at least 42p per share (FY26: 39p)
 

    Oliver Gardey    
    Portfolio Manager, ICG Enterprise Trust    
    ICGT’s Portfolio demonstrated the resilient growth we seek against a volatile market backdrop. The Portfolio Return on a Sterling Basis was 3.6% for the six months, with Portfolio performance strengthening in Q2.

Supporting this growth is our diversification across multiple investment areas. Notable strong performers in Q2 include Brooks Automation (benefitting from demand for semiconductors), Greenix (pest control) and CohnReznick (accounting) – returns were not reliant on any single sector or investment thesis. Underlying portfolio companies continued to grow, with LTM revenue and EBITDA increasing by 11% and 16% respectively1.

We generated Total Proceeds of £84m in the period, and we have been selective in how we allocate our capital. We have a progressive dividend policy, executed £20m in buybacks in the period and are continuing to invest across the cycle, making Total New Investments of £65m.

Economic and geopolitical uncertainty continue to impact private equity, which as an asset class is experiencing lower levels of transaction activity than it did in the decade running up to 2021. This environment makes our capital even more important to our underlying managers and reinforces the long-term nature of our partnership with them. With high liquidity and low net debt, ICGT has flexibility for new investments, buybacks and dividends to continue to optimise returns for shareholders.

1 EBITDA, based on Enlarged Perimeter covering 69% of the Portfolio

   

PERFORMANCE OVERVIEW

        Annualised
Performance to 31 July 2026 3 months 6 months 1 year 3 years 5 years 10 years
Portfolio Return on a Local Currency Basis 3.3% 3.2% 6.1% 6.8% 10.2% 14.7%
NAV per Share Total Return 3.3% 3.3% 4.4% 5.0% 8.4% 12.2%
Share Price Total Return 8.9% (4.8)% (0.6)% 10.0% 8.7% 12.2%
FTSE All-Share Index Total Return 5.6% 7.9% 21.6% 15.6% 11.6% 8.6%

Half-year ended: Jul 2022 Jul 2023 Jul 2024 Jul 2025 Jul 2026
Fund performance

Portfolio return (local currency) 7.4% 4.6% 3.8% 2.1% 3.2%
Portfolio return (sterling) 12.4% 1.6% 2.6% 0.1% 3.6%
NAV £1,269m £1,290m £1,274m £1,286m £1,272m
NAV per Share Total Return (%) 10.9% 0.8% 2.8% (0.7)% 3.3%
             
Investment activity

New Investments £144m £64m £104m £113m £65m
As % opening Portfolio 12% 5% 8% 7% 5%
Total Proceeds £107m £94m £86m £222m £84m
As % opening Portfolio 9% 7% 6% 15% 6%
             
Shareholder returns

Closing share price 1,166p 1,174p 1,340p 1,488p 1,440p
Total declared dividends per share 14p 16p 17p 18p 19p
Share Price Total Return (1.6)% 2.9% 10.3% 12.6% (4.8)%
Total shareholder distributions £15m £17m £33m £28m £33m
As % opening NAV 1% 1% 3% 2% 3%

Period ended 31 July 2026 Primary Direct Secondary Total ICG-managed
Local Currency return 2.6% 6.8% (3.2)% 3.2% 6.2%
Sterling return 2.8% 7.4% (2.2)% 3.6% 6.5%
New Investments £32m £14m £19m £65m £21m
Total Proceeds £49m £22m £13m £84m £39m
New Fund Commitments £104m — — £104m £22m
Closing Portfolio value £703m £483m £197m £1,383m £407m
% Total Portfolio 50.9% 34.9% 14.2% 100.0% 29.4%

COMPANY TIMETABLE
A presentation for investors and analysts will be held at 11:30 BST today. A link for the presentation can be found on the Results & Reports page of the Company website. A recording of the presentation will be made available on the Company website after the event.

  FY27 Second Interim Dividend
Ex-dividend date 12 November 2026
Record date 13 November 2026
Dividend payment date 27 November 2026

ENQUIRIES
Institutional investors and analysts:         Martin Li, Shareholder Relations                     +44 (0) 20 3545 1816
                                                                 Nathan Brown, Deutsche Numis                     +44 (0) 20 7260 1426
                                                                 David Harris, Cadarn Capital                           +44 (0) 20 7019 9042
Media:                                                      Clare Glynn, Corporate Communications        +44 (0) 20 3545 1850

ABOUT ICG ENTERPRISE TRUST
ICG Enterprise Trust is a leading listed private equity investor focused on creating long-term growth by delivering consistently strong returns through selectively investing in profitable, cash-generative private companies, primarily in Europe and the US, while offering the added benefit to shareholders of daily liquidity.

We invest in companies directly as well as through funds managed by ICG plc and other leading private equity managers who focus on creating long-term value and building sustainable growth through active management and strategic change.

NOTES

Included in this document are Alternative Performance Measures (“APMs”). APMs have been used if considered by the Board and the Manager to be the most relevant basis for shareholders in assessing the overall performance of the Company, and for comparing the performance of the Company to its peers and its previously reported results. The Glossary includes further details of APMs and reconciliations to UK-adopted International Accounting Standards (“IFRS”) measures, where appropriate.

In the Manager’s Review and Supplementary Information, all performance figures are stated on a Total Return basis (i.e. including the effect of re-invested dividends). ICG Alternative Investment Limited, a regulated subsidiary of Intermediate Capital Group plc, acts as the Manager of the Company.

DISCLAIMER
The information contained herein and on the pages that follow does not constitute an offer to sell, or the solicitation of an offer to acquire or subscribe for, any securities in any jurisdiction where such an offer or solicitation is unlawful or would impose any unfulfilled registration, qualification, publication or approval requirements on ICG Enterprise Trust PLC (the “Company”) or its affiliates or agents. Equity securities in the Company have not been and will not be registered under the applicable securities laws of the United States, Australia, Canada, Japan or South Africa (each an “Excluded Jurisdiction”). The equity securities in the Company referred to herein and on the pages that follow may not be offered or sold within an Excluded Jurisdiction, or to any U.S. person (“U.S. Person”) as defined in Regulation S under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or to any national, resident or citizen of an Excluded Jurisdiction.

The information on the pages that follow may contain forward looking statements. Any statement other than a statement of historical fact is a forward looking statement. Actual results may differ materially from those expressed or implied by any forward looking statement. The Company does not undertake any obligation to update or revise any forward looking statements. You should not place undue reliance on any forward looking statement, which speaks only as of the date of its issuance.

CHAIR’S FOREWORD

Dear fellow shareholders,

ICG Enterprise Trust’s NAV per Share Total Return was 3.3% for the six months to 31 July 2026. The growth was driven by a number of co-investments spread across multiple investment areas as well as by the £20m of accretive buybacks we executed during the period. The performance is discussed in more detail in the Investment Manager’s Review.

I believe our portfolio composition remains one of the key attractions of ICGT. We are not a sector-specific or theme-specific investor; instead we focus on company characteristics, such as profitability and strong cash generation. This should offer more resilience in the face of market headwinds.

As a Board we are focused on ensuring ICGT is positioned to deliver attractive long-term growth, with disciplined capital allocation across new investments, buybacks and dividends. During the period we made £65m Total New Investments, and returned £33m to shareholders: £13m through our progressive dividend policy and £20m through our two buyback programmes.

Over the last five years, ICGT has generated a cumulative 49% NAV per Share Total Return and a 52% Share Price Total Return, representing 8.4% and 8.7% respectively on an annualised basis.

In June 2026, the Company announced a 20% reduction in the management fee cap, to be implemented over the next two financial years. From 1 February 2027 the management fee cap will be reduced to 1.125% of NAV and from 1 February 2028 the cap will be reduced to 1.00% of NAV.

There has been significant attention recently on structures that give individual investors access to alternative investments, including private equity. While much of the debate has focused on newer fund structures, investment trusts have provided access to private markets for many years and continue to offer a differentiated proposition for long-term investors. As a Board and Manager, we continue to work hard to increase demand for our shares and welcome efforts across the industry to improve awareness, understanding and accessibility of investment trusts.

On behalf of the Board, thank you for your continued support.

Jane Tufnell
Chair
6 October 2026

MANAGER’S REVIEW

Alternative Performance Measures
The Board and the Manager monitor the financial performance of the Company on the basis of Alternative Performance Measures (APM), which are non-IFRS measures. The APM predominantly form the basis of the financial measures discussed in this review, which the Board believes assists shareholders in assessing their investment and the delivery of the investment strategy.

The Company holds certain investments in subsidiary entities. The substantive difference between APM and IFRS is the treatment of the assets and liabilities of these subsidiaries. The APM basis “looks through” these subsidiaries to the underlying assets and liabilities they hold, and it reports the investments as the Portfolio APM, gross of the liability in respect of the Co-investment Incentive Scheme. Under IFRS, the Company and its subsidiaries are reported separately. The assets and liabilities of the subsidiaries, which include the liability in respect of the Co-investment Incentive Scheme, are presented on the face of the IFRS balance sheet as a single carrying value. The same is true for the IFRS and APM basis of the Cash flow statement.

The following table sets out IFRS metrics and the APM equivalents:

IFRS (£m) 31 July 2026 31 July 2025 APM (£m) 31 July 2026 31 July 2025
Investments 1,341.6 1,361.5 Portfolio 1,382.9 1,415.6
NAV 1,271.9 1,286.3      
Cash flows from the sale of portfolio investments 14.6 42.5 Total Proceeds 83.8 222.2
Cash flows related to the purchase of portfolio investments 18.6 17.5 Total New Investment 65.0 113.1
           

The Glossary includes definitions for all APM and, where appropriate, a reconciliation between APM and IFRS.

Why private equity
Every day the lives of those living and working in the US and Western Europe are touched by companies owned by private equity: retailers, payments processors, home security, pet food, health services – the list is long. What typically unites these businesses is that they are profitable and cash generative. These businesses are actively managed by their shareholders, with management teams heavily incentivised to generate returns. Increasingly companies with these characteristics are choosing to grow under private equity ownership and to stay private for longer. Within that, ICGT focuses on a subset of those companies that we expect will generate resilient growth. As more businesses are owned by private equity, we believe it is a structurally attractive allocation within an investment portfolio, with a track record of attractive returns, and significant opportunity to continue that trajectory.

A share in ICGT gives you access to a unique portfolio of private companies.

Our investment strategy
Within developed markets, we focus on investing in buyouts of profitable, cash-generative businesses that exhibit resilient growth characteristics, which we believe will generate strong long-term compounding returns across economic cycles.

We take an active approach to Portfolio construction, with a flexible mandate that enables us to deploy capital in Primary, Secondary and Direct Investments. Geographically, we focus on the developed markets of North America and Europe which have deep and mature private equity markets.

  Medium-term target Five-year average2 31 July 2026
Target Portfolio composition1      
Investment category      
Primary ~40-50% 53% 51%
Direct ~30-35% 31% 35%
Secondary ~25-30% 16% 14%
Geography      
North America ~50% 46% 49%
Europe (inc. UK) ~50% 48% 46%
Other — 6% 5%
1. As a percentage of Portfolio
2. Five year average is the linear average of FY exposures for FY23 – FY26 and H1 FY27

ICG Enterprise Trust benefits from access to ICG-managed funds and Direct investments, which represented 29.4% of the Portfolio value at period end and generated a 6.2% return on a local currency basis.

Performance overview

At 31 July 2026, our Portfolio was valued at £1,383m, and the Portfolio Return on a Local Currency Basis for the first half of the financial year was 3.2% (H1 FY26: 2.1%).

Due to the geographic diversification of our Portfolio, the reported value is impacted by changes in foreign exchange rates. During the period, FX movements affected the Portfolio positively by £5.7m, driven primarily by appreciation of the US Dollar. In Sterling terms, Portfolio growth during the period was 3.6%.

The net result for shareholders was that ICG Enterprise Trust generated a NAV per Share Total Return of 3.3% during H1 FY27, ending the period with a NAV per Share of 2,091p.

Movement in the Portfolio
£m
Six months to 31 July 2026 Six months to 31 July 2025
Opening Portfolio 1,352.9 1,523.1
Total New Investments 65.0 113.1
Total Proceeds (83.8) (222.2)
Portfolio net cashflow (18.8) (109.1)
Valuation movement1 43.1 31.7
Currency movement 5.7 (30.1)
Closing Portfolio 1,382.9 1,415.6
1 92% of the Portfolio valuations are dated 30 June 2026 or later (H1 FY26: 92%)

NAV per Share Total Return Six months to
31 July 2026
Six months to
31 July 2025
% Portfolio growth (local currency) 3.2% 2.1%
% currency movement 0.4% (2.0)%
% Portfolio growth (Sterling) 3.6% 0.1%
Impact of gearing 0.2% —%
Finance costs and other expenses (0.4)% (0.7)%
Management fee (0.5)% (0.6)%
Co-investment Incentive Scheme Accrual (0.3)% (0.2)%
Impact of share buybacks 0.7% 0.7%
NAV per Share Total Return 3.3% (0.7)%

For Q2 the Portfolio Return on a Local Currency Basis was 3.3% and the NAV per Share Total Return was 3.3%.

Executing our investment strategy

Commitments
in the period
Total New Investments
in the period
Growth
in the period
Total Proceeds
in the period
Making commitments to funds, which expect to be drawn over 3 to 5 years Cash deployments into portfolio companies, either through funds or directly Driving growth and value creation of our portfolio companies Cash realisations of investments in Portfolio companies, plus Fund Disposals
£104m
(H1 FY26: £108m)
£65m
(H1 FY26: £113m)
£43m
(H1 FY26: £32m)
£84m
(H1 FY26: £222m)

Commitments
Our structure and flexible investment mandate enables us to commit through the cycle, maintaining vintage diversification for our Portfolio and sowing the seeds for future growth.

During the period we made nine new fund Commitments totalling £104m, including £22m to funds managed by ICG plc, as detailed below:

Fund Manager Commitment during the period    
    Local currency £    
ICG Europe IX ICG €25.0m £21.5m    
Gridiron VI Gridiron $25.0m £18.7m    
The Resolute Fund VII TJC $20.0m £14.9m    
Archimed Med Platform III Archimed €15.0m £12.8m    
Valeas II Valeas $15.0m £11.2m    
SkyKnight V SkyKnight $10.0m £7.5m    
Cinven Strategic Fund 2 Cinven €10.0m £8.6m    
Archimed Med IV Archimed €5.0m £4.3m    
InvestIndustrial LMM IV Investindustrial €5.0m £4.3m    

At 31 July 2026, ICG Enterprise Trust had outstanding Undrawn Commitments of £701m, of which £522m were to funds within their Investment Periods and £179m to funds outside their Investment Periods:

Movement in outstanding Commitments Year to 31 July 2026 £m
Undrawn Commitments as at 1 February 2026 635.3
New Fund Commitments 104.0
New Commitments relating to Co-investments 15.0
Drawdowns (65.0)
Currency and other movements, including repayment of commitments which can be reinvested 11.7
Undrawn commitments as at 31 July 2026 701.0
Undrawn Commitments – funds in Investment Period 522.0
Undrawn Commitments – funds outside Investment Period 179.0

ICGT’s overcommitment ratio at 31 July 2026 was 40.2% (31 July 2025: 30.6%), with the increase driven by maintaining commitments to our managers against a backdrop of continued lower investment activity:

  31 July 2026
£m
31 July 2025
£m
Total Undrawn Commitments 701.0 581.5
Total available liquidity (including facility) (190.2) (187.4)
Overcommitment net of total available liquidity 510.8 394.1
Overcommitment % of net asset value 40.2% 30.6%

Commitments are made in the funds’ underlying currencies. The currency split of the undrawn commitments at 31 July 2026 was as follows:

  31 July 2026 31 July 2025
Undrawn Commitments £m % £m %
US Dollar 412.4 58.8% 320.9 55.2%
Euro 263.1 37.6% 234.7 40.4%
Sterling 25.5 3.6% 25.9 4.4%
Total 701.0 100.0% 581.5 100.0%

Investments
Total New Investments of £65m were made during the period, of which £21m (32%) were into ICG managed investments. New investment by category detailed in the table below:

Investment Category Cost (£m) % of New Investments
Primary 31.8 49.0%
Direct 14.2 21.8%
Secondary 19.0 29.2%
Total 65.0 100.0%

The largest underlying company new investment is listed below. No other new underlying company investments in the period were above £1.0m:

Investment Description Manager Country Cost £m1
Pharmacy2U Operator of an online pharmacy business G Square United Kingdom 13.0

1 Represents ICG Enterprise Trust’s indirect investment (share of fund cost) plus any direct investments in the period.

Growth
The portfolio grew by £43 million (+3.2%) on a Local Currency Basis in the six months to 31 July 2026.

Growth across the Portfolio was split as follows:

  • By investment type: growth was spread across Direct 6.8% and Primary 2.6%, offset by Secondary (3.2)%
  • By geography: North America and Europe experienced growth of 0.6% and 6.5% respectively

Key contributors to portfolio growth in the period include Exail and Ambassador Theatre Group, where valuations were marked up to the expected sale price.

The growth in the Portfolio is underpinned by the performance of our Portfolio companies, which delivered robust financial performance during the period:

  Top 30 Enlarged Perimeter
Portfolio coverage 38% 69%
Last Twelve Months (‘LTM’) revenue growth 8.4% 11.3%
LTM EBITDA growth 13.7% 16.2%
Net Debt / EBITDA 4.8x 4.8x
Enterprise Value / EBITDA 16.7x 15.8x
Note: values are weighted averages for the respective portfolio segment; see Glossary for definition and calculation methodology

Quoted company exposure

We do not actively invest in publicly quoted companies but gain listed investment exposure when IPOs are used as a route to exit an investment. In these cases, exit timing typically lies with the manager with whom we have invested.

At 31 July 2026, ICG Enterprise Trust’s exposure to quoted companies was valued at £31.3m, equivalent to 2.3% of the Portfolio value (31 January 2026: 3.9%). Exposure to Chewy, our largest listed exposure, decreased from 1.2% of Portfolio Value at 31 January 2026 to 0.8% at 31 July 2026, driven predominantly by a 23% decline in its share price in the period.

At 31 July 2026 Chewy was the only quoted investment that individually accounted for 0.5% or more of the Portfolio value:

Company Ticker 31 July 2026
% of Portfolio value
Chewy CHWY-US 0.8%
Other companies   1.5%
Total   2.3%

Realisations
During the first half of FY27, the ICG Enterprise Trust Portfolio generated Total Proceeds of £84m. The biggest contributor was the exit of Curium Pharma, a Direct investment alongside ICG Strategic Equity III, which generated proceeds of £23m in the period.

Realisation activity during the period included 24 Full Exits generating proceeds of £55m. These were completed at a weighted average Uplift to Carrying Value of 9.4% and represent a weighted average Multiple to Cost of 3.0x for those investments. Realisation activity over the last twelve months included 60 Full Exits, which were completed at a weighted average Uplift to Carrying Value of 10% and represented a weighted average Multiple to Cost of 3.1x.

The five largest underlying realisations in the period were as follows:

Realisation Description Manager Country Proceeds £m1
Curium Pharma Supplier of nuclear medicine diagnostic pharmaceuticals ICG United Kingdom 23.3
Yudo Manufacturer of hot runner systems ICG South Korea 8.5
SGB-SMIT Manufacturer of transformers for electricity power transmission and distribution One Equity Partners Germany 5.1
PSB Academy Provider of private tertiary education ICG Singapore 4.1
Hanson Wade Organiser of B2B conferences for pharmaceutical and biotech industries Graphite United Kingdom 3.4
Total of 5 largest underlying realisations   44.4

1 Represents the total direct and indirect proceeds received from each investment by ICG Enterprise Trust

Balance sheet and liquidity

Net assets at 31 July 2026 were £1,271.9m, equal to 2,091p NAV per share.

At 31 July 2026, the drawn debt was £85.8m (31 January 2026: £66.6m), resulting in a net debt position of £66.4m (31 January 2026: £32.8m). At 31 July 2026, the Portfolio represented 109% of net assets (31 January 2026: 106%).

  £m % of net assets
Portfolio 1,382.9 108.7%
Cash 19.4 1.5%
Drawn debt (85.8) (6.7)%
Co-investment Incentive Scheme Accrual (41.6) (3.3)%
Other net current liabilities (3.0) (0.2)%
Net assets 1,271.9 100.0%

Our objective is to be fully invested through the cycle, while ensuring that we have sufficient financial resources to be able to take advantage of attractive investment opportunities as they arise.

ICG Enterprise Trust has access to a €300m credit facility. During the period the maturity was extended by a year to May 2030. The drawn margin has decreased to 290bps (from 300-320bps). The fee on undrawn amounts remains 115bps.

At 31 July 2026, ICG Enterprise Trust had a cash balance of £19.4m (31 January 2026: £33.8m) and total available liquidity of £190.2m (31 January 2026: £227.1m).

  £m
Cash at 31 January 2026 33.8
Total Proceeds 83.8
New investments (65.0)
Net debt drawn down 19.2
Dividends and buybacks (32.7)
Management fees (7.9)
FX and other expenses (11.8)
Cash at 31 July 2026 19.4
Available undrawn debt facilities 170.8
Total available liquidity 190.2

Dividend and share buyback
ICG Enterprise Trust has a progressive dividend policy alongside two share buyback programmes to return capital to shareholders.

Dividends
The Board has declared a dividend of 9.5p per share in respect of the second quarter, taking total dividends for the period to 19p (H1 FY26: 18p). It remains the Board’s intention to declare total dividends of at least 42p per share for the financial year, which would be an increase of 8% on the previous financial year (FY26: 39p).

Share buybacks
The following purchases have been made under the Company’s share buyback programme:

  Long-term Opportunistic Total
  H1 FY273 Since inception1 H1 FY273 Since inception2 H1 FY273 Since
inception
Number of shares purchased 504,421 4,258,610 894,735 3,418,131 1,399,156 7,676,741
% of opening shares since buyback started         2.0% 11.2%
Capital returned to shareholders £7.2m £53.6m £12.8m £45.0m £20.0m £98.6m
Number of days shares have been acquired 40 304 10 33 50 337
Weighted average discount to last reported NAV 30.9% 35.9% 31.0% 33.8% 31.0% 34.9%
NAV per Share accretion (p)         14.9 90.3
NAV per Share accretion (% of NAV)         0.7% 4.5%

1. Since October 2022 (which was when the long-term share buyback programme was launched) up to and including 31 July 2026.
2. Since May 2024 (which was when the opportunistic buyback programme was launched) up to and including 31 July 2026.
3. Based on date of settlement.
Note: aggregate consideration excludes commission, PTM and SDRT.

Voting of shares held in CT Savings Plans
In line with the majority of other investment trusts with substantial CT Savings Plan shareholdings, the Board has accepted the application of proportional voting by the plan administrator of the various CT Savings Plans. This will be applied in accordance with the terms of such plans.

Foreign exchange rates

The details of relevant FX rates applied in this report are provided in the table below:

  Average rate for six months to Period end rate
  31 July 2026 31 July 2025 31 July 2026 31 July 2025
GBP:EUR 1.1563 1.1807 1.1696 1.1571
GBP:USD 1.3424 1.3171 1.3483 1.3207
EUR:USD 1.1610 1.1161 1.1527 1.1416

Activity since the period end
Notable activity between 1 August 2026 and 31 August 2026 included: One new fund commitment of £45m; Total New Investments of £2.5m; and Total Proceeds of £6.7m.

ICG Private Equity Fund Investments Team
6 October 2026

SUPPLEMENTARY INFORMATION

This section presents supplementary information regarding the Portfolio (see Manager’s Review and the Glossary for further details and definitions).

Portfolio composition

Portfolio by calendar year of investment % of value of underlying investments
31 July 2026
% of value of underlying investments
31 July 2025
2026 5.0% —%
2025 11.6% 5.2%
2024 11.5% 10.8%
2023 8.3% 8.0%
2022 18.7% 19.0%
2021 22.3% 24.1%
2020 6.4% 8.6%
2019 7.5% 9.6%
2018 3.0% 4.4%
2017 and older 5.7% 10.3%
Total 100.0% 100.0%

Portfolio by sector % of value of underlying investments
31 July 2026
% of value of underlying investments
31 July 2025
TMT 27.7% 29.0%
Consumer goods and services 15.3% 17.1%
Healthcare 12.3% 13.3%
Industrials 10.3% 8.6%
Business services 10.0% 10.2%
Financials 8.8% 9.3%
Education 4.9% 5.8%
Leisure 2.2% 3.2%
Other 8.6% 3.5%
Total 100.0% 100.0%

Portfolio by fund currency1 31 July 2026
£m
31 July 2026
%
31 July 2025
£m
31 July 2025
%
 
USD 778.7 56.3% 780.9 55.2%  
EUR 491.7 35.6% 507.8 35.9%  
GBP 112.5 8.1% 126.8 9.0%  
Total 1,382.9 100.0% 1,415.6 100.0%  
1 Currency exposure by reference to the reporting currency of each fund or direct investment.  

Portfolio Dashboard

The tables below provide disclosure on the composition and dispersion of financial and operational performance for the Top 30 and the Enlarged Perimeter. At 31 July 2026, the Top 30 Companies represented 38% of the Portfolio by value and the Enlarged Perimeter represented 69% of total Portfolio value. This information is prepared on a value-weighted basis, based on contribution to Portfolio value at 31 July 2026.

  % of value at 31 July 2026
Sector exposure Top 30 Enlarged Perimeter
TMT 36.6% 29.7%
Consumer goods and services 11.0% 13.2%
Business services 19.0% 12.9%
Industrials 15.8% 15.4%
Healthcare 8.0% 11.0%
Leisure 3.1% 3.2%
Education 6.5% 6.8%
Financials —% 4.2%
Other — % 3.6%
Total 100.0% 100.0%

  % of value at 31 July 2026
Geographic exposure1 Top 30 Enlarged Perimeter
North America 47.7% 46.2%
Europe 52.3% 52.9%
Other —% 0.9%
Total 100.0% 100.0%
1 Geographic exposure is calculated by reference to the location of the headquarters of the underlying Portfolio companies

    % of value at 31 July 2026
LTM revenue growth Top 30 Enlarged Perimeter
<0% 20.4% 20.0%
0-10% 48.3% 40.0%
10-20% 10.0% 14.0%
20-30% 12.1% 9.1%
>30% 6.9% 10.4%
n.a 2.3% 6.6%
Weighted average 8.4% 11.3%
Note: for consistency, any excluded investments are excluded for all dispersion analysis.

    % of value at 31 July 2026
LTM EBITDA growth Top 30 Enlarged Perimeter
<0% 17.9% 17.3%
0-10% 42.9% 34.0%
10-20% 15.6% 18.5%
20-30% 3.2% 7.0%
>30% 18.3% 16.3%
n.a 2.3% 6.9%
Weighted average 13.7% 16.2%
Note: for consistency, any excluded investments are excluded for all dispersion analysis.
               

    % of value at 31 July 2026
EV/EBITDA multiple Top 30 Enlarged Perimeter
0-10x 6.3% 10.9%
10-12x 14.1% 13.9%
12-13x 8.1% 7.3%
13-15x 15.6% 17.1%
15-17x 14.6% 14.0%
17-20x 13.2% 11.3%
>20x 28.1% 21.1%
n.a. —% 4.5%
Weighted average 16.7x 15.8x
Note: for consistency, any excluded investments are excluded for all dispersion analysis.

    % of value at 31 July 2026
Net Debt / EBITDA Top 30 Enlarged Perimeter
<2x 14.7% 12.1%
2-4x 13.4% 15.7%
4-5x 21.3% 21.4%
5-6x 21.1% 18.3%
6-7x 18.2% 14.5%
>7x 11.3% 12.1%
n.a. —% 6.0%
Weighted average 4.8x 4.8x
Note: for consistency, any excluded investments are excluded for all dispersion analysis.

Top 30 companies

The table below presents the 30 companies in which ICG Enterprise Trust had the largest investments by value at 31 July 2026. The valuations are gross of underlying managers fees and carried interest.

  Company Manager Year of investment Country Value as a % of Portfolio
1 Exail        
  Provider of autonomous systems for the aerospace and maritime sectors ICG 2022 France 3.4%
2 Circana        
  Provider of mission-critical data and predictive analytics to consumer goods manufacturers New Mountain 2022 United States 2.2%
3 Visma        
  Provider of business management software and outsourcing services Hg / ICG 2017/ 2020 / 2024 Norway 2.0%
4 Ambassador Theatre Group        
  Operator of theatres and ticketing platforms ICG 2021 United Kingdom 1.7%
5 Davies Group        
  Provider of speciality business process outsourcing services BC 2021 United Kingdom 1.6%
6 Vistage        
  Provider of CEO leadership and coaching for small and mid-size businesses in the US Gridiron 2022 United States 1.6%
7 Crucial Learning        
  Provider of corporate training courses focused on communication skills and leadership development Leeds Equity 2019 United States 1.4%
8 Minimax        
  Supplier of fire protection systems and services ICG 2018 / 2024 / 2025 Germany 1.4%
9 Leaf Home Solutions        
  Provider of home maintenance services Gridiron 2016 / 2025 United States 1.4%
10 DomusVi        
  Operator of nursing homes ICG 2017 / 2021 France 1.3%
11 Brooks Automation        
  Provider of semiconductor manufacturing solutions TH Lee 2021 / 2022 United States 1.3%
12 KronosNet        
  Provider of tech-enabled customer engagement and business solutions ICG 2022 Spain 1.2%
13 Audiotonix        
  Manufacturer of audio mixing consoles PAI 2024 United Kingdom 1.2%
14 European Camping Group        
  Operator of premium campsites and holiday parks PAI 2021 / 2022 / 2023 / 2025 France 1.2%
15 Planet Payment        
  Provider of integrated payments services focused on hospitality and luxury retail Eurazeo / ICG 2021 Ireland 1.2%
16 Class Valuation        
  Provider of residential mortgage appraisal management services Gridiron 2021 United States 1.2%
17 Precisely        
  Provider of enterprise software Clearlake / ICG 2021 / 2022 United States 1.2%
18 DigiCert        
  Provider of enterprise security solutions ICG 2021 United States 1.1%
19 Multiversity        
  Provider of online higher education CVC / ICG 2024 Italy 1.0%
20 Newton        
  Provider of management consulting services ICG 2021 / 2022 United Kingdom 1.0%
21 Archer Technologies        
  Developer of governance, risk and compliance software intended for risk management Cinven 2023 United States 0.9%
22 Pharmacy2U        
  Operator of an online pharmacy business G Square 2026 United Kingdom 0.9%
23 Ping Identity        
  Provider of cyber security solutions Thoma Bravo 2022 / 2023 United States 0.9%
24 Dayforce        
  Provider of human capital management solutions Thoma Bravo 2026 United States 0.9%
25 Chewy        
  Online retailer of pet food and products BC 2014 / 2015 / 2022 United States 0.8%
26 Global Market Foods        
  Speciality distributor of international foods Audax 2026 United States 0.8%
27 Greenix        
  Provider of pest control services Gridiron Capital 2025 United States 0.8%
28 AMEOS Group        
  Operator of private hospitals ICG 2021 Switzerland 0.8%
29 AML RightSource        
  Provider of compliance and regulatory services and solutions Gridiron Capital 2020 United States 0.7%
30 Ivanti        
  Provider of IT management solutions Charlesbank Capital Partners / ICG 2021 United States 0.7%
  Total of the 30 largest underlying investments       37.7%

The 30 largest fund investments by value

The table below presents the 30 largest fund investments by value at 31 July 2026. The valuations are net of underlying managers’ fees and carried interest.

  Fund Year of commitment Value £m Outstanding commitment £m
1 ICG Europe VIII      
  Mezzanine and equity in mid-market buy-outs 2021 32.7 11.1
2 ICG Strategic Equities Fund IV      
  GP-led secondary transactions 2021 31.5 6.7
3 ICG LP Secondaries I      
  LP-led secondary transactions 2022 28.0 22.2
4 Advent Global Private Equity X      
  Large buyouts 2022 20.5 5.2
5 ICG Strategic Equities Fund V      
  GP-led secondary transactions 2023 19.4 24.9
6 Seventh Cinven      
  Large buyouts 2019 18.7 1.7
7 PAI Europe VII      
  Mid-market and large buyouts 2017 18.6 1.4
8 ICG Ludgate Hill (Feeder) Domino SCSp      
  Secondary portfolio 2025 17.8 4.2
9 CVC European Equity Partners VII      
  Large buyouts 2017 17.7 3.1
10 Oak Hill V      
  Mid-market buyouts 2019 17.6 0.4
11 Gridiron Capital Fund V      
  Mid-market buyouts 2022 16.6 1.7
12 Investindustrial VII      
  Mid-market buyouts 2019 16.3 3.9
13 ICG Augusta Partners Co-Investor**      
  Secondary fund restructurings 2018 16.1 16.1
14 Gridiron Capital Fund III      
  Mid-market buyouts 2016 15.9 1.2
15 ICG Ludgate Hill (Feeder B) Waterfall SCSp      
  Secondary portfolio 2021 15.9 13.9
16 Resolute V      
  Mid-market buy-outs 2021 15.7 0.6
17 ICG Strategic Equities Fund III      
  GP-led secondary transactions 2018 14.7 10.3
18 Graphite Capital Partners VIII*      
  Mid-market buyouts 2013 14.6 4.1
19 BC Partners Fund XI      
  Large Buyouts 2021 14.5 1.3
20 CVC Capital Partners VIII      
  Large buyouts 2020 14.5 0.5
21 ICG Europe Mid-Market Fund      
  Mezzanine and equity in mid-market buyouts 2019 14.4 4.9
22 ICG Ludgate Hill (Feeder) II Boston SCSp      
  Secondary portfolio 2022 14.3 5.0
         
23 Gridiron Capital Fund IV      
  Mid-market buyouts 2019 14.0 0.4
24 PAI Europe VIII      
  Mid-market and large buyouts 2022 13.8 9.8
25 Thomas H Lee Equity Fund IX      
  Mid-market and large buyouts 2021 13.6 4.0
26 ICG Ludgate Hill (Feeder) IIIA Porsche SCSp      
  Secondary portfolio 2022 13.4 5.2
27 Advent Global Private Equity IX      
  Large buyouts 2019 13.4 0.4
28 Graphite Capital Partners IX      
  Mid-market buyouts 2018 13.1 0.5
29 ICG Europe VII      
  Mezzanine and equity in mid-market buyouts 2018 12.6 5.8
30 Oak Hill VI (Offshore)      
  Mid-market buy-outs 2024 11.9 1.7
  Total of the largest 30 fund investments   512.2 172.5
  Percentage of total investment Portfolio   37.0%  

* Includes the associated top up funds

** All or part of interest acquired through a secondary purchase

PRINCIPAL RISKS AND UNCERTAINTIES

The principal risks and uncertainties facing the Company are substantially the same as those disclosed in the Strategic Report and in the notes to the Financial Statements in the Company’s latest Annual Report for the year ended 31 January 2026 which was approved by the Board on 6 May 2026.

The Company considers its principal risks (as well as several underlying risks comprising each principal risk) in four categories:

Investment risks: the risk to performance resulting from ineffective or inappropriate investment selection, execution or monitoring.

External risks: the risk of failing to deliver the Company’s investment objective and strategic goals due to external factors beyond the Company’s control.

Operational risks: the risk of loss resulting from inadequate or failed internal processes, people or systems and external event, including regulatory risk.

Financial risks: the risks of adverse impact on the Company due to having insufficient resources to meet its obligations or counterparty failure and the impact any material movement in foreign exchange rates may have on underlying valuations.

A comprehensive risk assessment process is undertaken regularly to re-evaluate the impact and probability of each risk materialising and the strategic, financial and operational impact of the risk. Where the residual risk is determined to be outside of appetite, appropriate action is taken.

In addition to these, emerging risks are regularly considered to assess any potential impact on the Company and to
determine whether any actions are required. The Board also regularly considers the evolution of requirements and standards
relating to ESG and responsible investing.

Related Party Transactions

There have been no material changes in the related party transactions described in the 31 January 2026 Annual Report.

Directors’ Responsibility Statement

The Directors are responsible for preparing the Interim Report, in accordance with applicable laws and regulations. The Directors confirm that, to the best of their knowledge:

  • The condensed interim financial statements have been prepared in accordance with UK-adopted IAS 34 Interim condensed financial statements and gives a true and fair view of the assets, liabilities, financial position and profit or loss of the Company;
  • The Chair’s Statement and Manager’s Review includes a fair review of the information required by DTR 4.2.7R of the Disclosure Guidance and Transparency Rules, being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed interim financial statements, and a description of the principal risks and uncertainties for the remaining six months of the year; and
  • The interim financial statements include a fair review of the information required by DTR 4.2.8R of the Disclosure Guidance and Transparency Rules, being related party transactions that have taken place in the first six months of the financial year and that have materially affected the financial position or performance of the Company during that period, and any changes in the related party transactions described in the last Annual Report that could do so.

The Interim Report was approved by the Board and the above Directors’ Responsibility Statement was signed on its behalf by the Chair.

Jane Tufnell
Chair

7 October 2026

Unaudited Interim Financial Statements for the period ended 31 July 2026

INTERIM CONDENSED FINANCIAL STATEMENTS

Income statement

Half year to 31 July 2026
(Unaudited)
Half year to 31 July 2025
(Unaudited)
               
  Notes Revenue
return
£’000
Capital return
£’000
Total

£’000

Revenue
return
£’000
Capital return
£’000
Total

£’000

Investment returns              
Income, gains and losses on investments 7 (54) 45,578 45,524 491 (5,875) (5,384)
Deposit interest   85 — 85 54 — 54
Other income   — — — 96 — 96
Foreign exchange gains and losses   — (802) (802) — 2,205 2,205
    31 44,776 44,807 641 (3,670) (3,029)
Expenses              
Investment management charges   (787) (7,088) (7,875) (800) (7,204) (8,005)
Other expenses including finance costs   (1,320) (3,362) (4,682) (1,889) (5,188) (7,077)
    (2,107) (10,450) (12,557) (2,689) (12,392) (15,081)
               
Profit/(loss) before tax   (2,076) 34,326 32,250 (2,048) (16,062) (18,110)
Taxation   — — — — — —
Profit/(loss) for the period   (2,076) 34,326 32,250 (2,048) (16,062) (18,110)
Attributable to:              
Equity shareholders   (2,076) 34,326 32,250 (2,048) (16,062) (18,110)
Basic and diluted earnings per share 5     52.67p     (28.47p)
               
               
               
               
               
               
               
               
               

The columns headed ‘Total’ represent the income statement for the relevant financial periods and the columns headed ‘Revenue return’ and ‘Capital return’ are supplementary information in line with guidance published by the AIC. There is no Other Comprehensive Income.

All profits are from continuing operations.

The notes on pages 26 to 29 form an integral part of the interim financial statements.

Balance sheet

  Notes 31 July
2026
(unaudited)

£’000

31 January
2026
(audited)

£’000

Non-current assets      
Investments held at fair value 7 1,341,624 1,308,900
Current assets      
Cash and cash equivalents   19,439 33,837
Prepayments and receivables   1,461 1,486
    20,900 35,323
Current liabilities      
Borrowings   85,806 66,570
Payables   4,792 5,081
    90,598 71,651
Net current assets/(liabilities)   (69,698) (36,328)
Total assets less current liabilities   1,271,926 1,272,572
Capital and reserves      
Share capital   6,355 6,355
Capital redemption reserve   3,049 3,049
Share premium   12,936 12,936
Capital reserve   1,259,576 1,258,146
Revenue reserve   (9,990) (7,914)
Total equity   1,271,926 1,272,572
Net asset value per share (basic and diluted) 6 2,090.6p 2,044.6p
       
       
       
       
       
       
       
       
       
       

The notes on pages 26 to 29 form an integral part of the interim financial statements.

The financial statements on pages 22 to 29 were approved by the Board of Directors on 06 October 2026 and signed on its behalf by:

Jane Tufnell        Alastair Bruce
Director                Director

Cash flow statement

  Note Half year to
31 July 2026
(unaudited)
£’000
Half year to
31 July 2025
(unaudited)
£’000
Operating activities      
Sale of portfolio investments   14,578 42,464
Purchase of portfolio investments   (18,583) (17,549)
Cash flow to subsidiaries’ investments   (52,535) (101,245)
Cash flow from subsidiaries’ investments   69,060 179,266
Interest income received from portfolio investments   27 212
Dividend income received from portfolio investments   91 286
Other income received   59 150
Investment management charges paid   (7,878) (8,139)
Other expenses paid   (1,069) (2,117)
Net cash inflow from operating activities   3,750 93,328
Financing activities      
Credit facility fee paid   (941) (1,294)
Interest paid   (2,731) (769)
Credit Facility utilised   39,421 88,055
Credit Facility repaid   (20,184) (137,139)
Purchase of shares into treasury   (20,029) (15,937)
Equity dividends paid 4 (12,867) (12,086)
Net cash outflow from financing activities   (17,331) (79,170)
Net (decrease)/increase in cash and cash equivalents   (13,581) 14,158
Cash and cash equivalents at beginning of year   33,837 3,927
Net (decrease)/increase in cash and cash equivalents   (13,581) 14,158
Effect of changes in foreign exchange rates   (817) 2,767
Cash and cash equivalents at end of period   19,439 20,852

The notes on pages 26 to 29 form an integral part of the interim financial statements.

Statement of changes in equity

  Share capital
£’000
Capital redemption
reserve
£’000
Share premium
£’000
Capital reserve
£’000
Revenue
reserve
£’000
Total
shareholders’
equity
£’000
Half year to 31 July 2026
(Unaudited)
Opening balance at 1 February 2026 6,355 3,049 12,936 1,258,146 (7,914) 1,272,572
Profit for the period and total comprehensive income — — — 34,326 (2,076) 32,250
Transfer to capital redemption reserve — — — — — —
Dividends paid or approved — — — (12,867) — (12,867)
Purchase of shares into treasury — — — (20,029) — (20,029)
Closing balance at 31 July 2026 6,355 3,049 12,936 1,259,576 (9,990) 1,271,926
             
             
  Share capital
£’000
Capital redemption
reserve
£’000
Share premium
£’000
Capital reserve
£’000
Revenue
reserve
£’000
Total
shareholders’
equity
£’000
Half year to 31 July 2025
(Unaudited)
Opening balance at 1 February 2025 7,292 2,112 12,936 1,315,727 (5,674) 1,332,393
Loss for the period and total comprehensive income — — — (16,062) (2,048) (18,110)
Transfer to capital redemption reserve (937) 937 — —   —
Dividends paid or approved — — — (12,086) — (12,086)
Purchase of shares into treasury — — — (15,937) — (15,937)
Closing balance at 31 July 2025 6,355 3,049 12,936 1,271,642 (7,722) 1,286,260

The notes on pages 26 to 29 form an integral part of the interim financial statements.

NOTES TO THE FINANCIAL STATEMENTS

For the period ended 31 July 2026

1 GENERAL INFORMATION

These interim condensed financial statements relate to ICG Enterprise Trust plc (‘the Company’). ICG Enterprise Trust plc is registered in England and Wales and is incorporated in the United Kingdom. The Company is domiciled in the United Kingdom and its registered office is Procession House, 55 Ludgate Hill, London EC4M 7JW. The Company’s objective is to provide long-term growth by investing in private companies managed by leading private equity managers.

2 FINANCIAL INFORMATION

The interim condensed financial statements are unaudited and do not comprise statutory accounts within the meaning of section 434 of the Companies Act 2006. Within the notes to the interim condensed financial statements, all current and comparative data covering the period to (or as at) 31 July 2026 is unaudited. Data given in respect of the year to 31 January 2026
is audited. The statutory accounts for the year to 31 January 2026 have been reported on by Ernst & Young LLP and delivered to the Registrar of Companies. The report of the auditors was (i) unqualified, (ii) did not contain an emphasis of matter paragraph, and (iii) did not contain any statements under section 498(2) or (3) of the Companies Act 2006.

3 BASIS OF PREPARATION

The interim financial statements have been prepared in accordance with UK-adopted IAS 34 Interim Financial Reporting (“IAS 34”) and on the basis of the accounting policies and methods of computation set out in the financial statements of the Company for the year to 31 January 2026.

The financial information for the year ended 31 January 2026 was prepared in accordance with UK-adopted International Accounting Standards (‘IFRS’) and the Statement of Recommended Practice (‘SORP’) for investment trusts issued by the Association of Investment Companies in July 2022.

The Company comprises one operating segment which is also a reporting segment.

Going concern

These financial statements have been prepared on a going concern basis. In making their going concern assessment, the Directors have considered the potential impact of principal risks on the Company’s business activities; the Company’s net cash position; the availability of the Company’s credit facility and compliance with its covenants; and the Company’s cash flow projections, in particular those arising from committed but undrawn commitments.

The Directors have concluded based on the above assessment that the preparation of the interim condensed financial statements on a going concern basis, to 31 October 2027, a period of more than 12 months from the signing of the interim condensed financial statements, continues to be appropriate.

4 DIVIDENDS

  Half year to
31 July
2026
£’000
Half year to
31 July
2025
£’000
Third quarterly dividend in respect of year ended 31 January 2026: 9p per share (2025: 8.5p) 5,567 5,460
Final dividend in respect of year ended 31 January 2026 of 12p per share (2025: 10.5p) 7,300 6,626
Total 12,867 12,086

The interim dividend for the quarter to 30 April 2026 was 9.5p per share (totalling £5.77m), paid on 28 August 2026 to shareholders on the register on 14 August 2026. The Board has approved a second interim dividend of 9.5p per share in respect of the year ended 31 January 2027 which will be paid on 27 November 2026 to shareholders on the register at the close of business on 13 November 2026.

5 EARNINGS PER SHARE

Earnings per share Half year to 31 July 2026 Half year to 31 July 2025
Revenue return per ordinary share (3.39p) (3.22p)
Capital return per ordinary share 56.06p (25.25p)
Earnings per ordinary share (basic and diluted) 52.67p (28.47p)
Weighted average number of shares 61,232,982 63,601,224

Revenue return per ordinary share is calculated by dividing the revenue return attributable to equity shareholders of £(2.1)m (2025: £(2.0)m) by the weighted average number of ordinary shares outstanding during the period.

Capital return per ordinary share is calculated by dividing the capital return attributable to equity shareholders of £34.3m (2025: £(16.1)m) by the weighted average number of ordinary shares outstanding during the period.

Basic and diluted earnings per ordinary share are calculated by dividing the earnings attributable to equity shareholders of £32.2m (2025: £(18.1)m) by the weighted average number of ordinary shares outstanding during the period.

The weighted average number of ordinary shares outstanding (excluding those held in treasury) during the year was 61,232,982 (2025: 63,601,224). There were no potentially dilutive shares, such as options or warrants, in either period.

6 NET ASSET VALUE PER SHARE

The net asset value per share is calculated on equity attributable to equity holders of £1,271.9m (31 January 2026: £1,272.6m) and on 60,840,314 (31 January 2026: 62,239,470) ordinary shares in issue at the period end. There were no potentially dilutive shares, such as options or warrants, at either period end. Calculated on both the basic and diluted basis the net asset value per share was 2,090.6p (31 January 2026: 2,044.6p).

7 FAIR VALUE ESTIMATION

IFRS 13 requires disclosure of fair value measurements of financial instruments categorised according to the following fair value measurement hierarchy:

  • Quoted prices (unadjusted) in active markets for identical assets or liabilities (level 1).
  • Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices) (level 2).
  • Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs) (level 3).

The valuation techniques applied to level 3 assets are described in note 1(c) of the annual financial statements. No investments were categorised as level 1 or level 2.

The Company’s policy is to recognise transfers into and transfers out of fair value hierarchy levels at the end of the reporting year when they are deemed to occur.

The following table presents the assets that are measured at fair value at 31 July 2026 and 31 January 2026:

  Level 1   Level 2   Level 3   Total
31 July 2026 £’000   £’000   £’000   £’000
Investments held at fair value              
Unquoted investments –   –   342,874   342,874
Subsidiary undertakings –   –   998,750   998,750
Total investments held at fair value –   –   1,341,624   1,341,624

  Level 1   Level 2   Level 3   Total
31 January 2026 £’000   £’000   £’000   £’000
Investments held at fair value              
Unquoted investments –   –   314,939   314,939
Subsidiary undertakings –   –   993,961   993,961
Total investments held at fair value –   –   1,308,900   1,308,900

Investments in level 3 securities are in respect of private equity fund investments and co-investments and are held at fair value. The primary basis for determining the fair value of an investment is the valuation estimate provided by the underlying manager of that investment. Adjustments are then made to that valuation for cash flow events occurring after the date of the manager’s valuation, such as realisations or liquidity-related adjustments.

The tables below analyse the movement in the carrying value of the Company’s investments in the year. In accordance with accounting standards, subsidiary undertakings of the Company are reported at fair value rather than on a ‘look-through’ basis.

An investee fund is considered to generate realised gains or losses if it is more than 85% drawn and has returned at least the amount invested by the Company. All gains and losses arising from the underlying investments of such funds are presented as realised. All gains and losses in respect of fund investments that have not satisfied the above criteria are presented as unrealised.

Direct Investments are considered to generate realised gains or losses when they are sold. Investments are held by both the Company and through its subsidiaries.

  Quoted
£’000
Unquoted
£’000
Subsidiary
undertakings
£’000
Total
£’000
Cost at 1 February 2026 — 183,897 160,089 343,986
Unrealised appreciation at 1 February 2026 — 131,042 833,872 964,914
Valuation at 1 February 2026 — 314,939 993,961 1,308,900
Movements in the period:        
Purchases — 18,552 52,483 71,035
Sales        
– capital proceeds — (14,775) (69,060) (83,835)
– realised gains/(losses) based on carrying value at previous
balance sheet date
— (2,412)   (2,412)
Movement in unrealised appreciation — 26,570 21,366 47,936
Valuation at 31 July 2026 — 342,874 998,750 1,341,624
Cost at 31 July 2026 — 187,674 143,511 331,185
Unrealised appreciation/ (depreciation) at 31 July 2026 — 155,200 855,239 1,010,439
Valuation at 31 July 2026 — 342,874 998,750 1,341,624

  Quoted
£’000
Unquoted
£’000
Subsidiary
undertakings
£’000
Total
£’000
Cost at 1 February 2025 — 193,458 325,637 519,095
Unrealised appreciation at 1 February 2025 — 111,771 838,683 950,454
Valuation at 1 February 2025 — 305,229 1,164,320 1,469,549
Movements in the period:        
Purchases — 21,398 91,665 113,063
Sales        
– capital proceeds — (42,463) (179,266) (221,729)
– realised gains/(losses) based on carrying value at previous
balance sheet date
— (1,002)   (1,002)
Movement in unrealised appreciation — (5,234) 6,885 1,651
Valuation at 31 July 2025 — 277,928 1,083,604 1,361,532
Cost at 31 July 2025 — 172,393 238,036 410,429
Unrealised appreciation/ (depreciation) at 31 July 2025 — 105,535 845,568 951,103
Valuation at 31 July 2025 — 277,928 1,083,604 1,361,532

  31 July 2026 31 July 2025    
  £’000 £’000    
Realised losses based on carrying values at previous balance sheet date (2,412) (1,002)    
Increase/(decrease) in unrealised appreciation 47,936 1,651    
Gains/(losses) on investments 45,524 649    

Gains on investments includes the ‘Realised loss based on carrying values at previous balance sheet date’, which meet the criteria set out on the previous page, together with the net fair value movement on the balance of the investee funds.

8 POST BALANCE SHEET EVENTS

There have been no material events since the balance sheet date.

GLOSSARY

Term Short form Definition
Alternative Performance Measures

APMs Alternative Performance Measures are a term defined by the European Securities and Markets Authority as “financial measures of historical or future performance, financial position, or cash flows, other than a financial measure defined or specified in the applicable financial reporting framework”.
APMs are used in this report if considered by the Board and the Manager to be the most relevant basis for shareholders in assessing the overall performance of the Company and for comparing the performance of the Company to its peers, taking into account industry practice.
Definitions and reconciliations to IFRS measures are provided in the main body of the report or in this Glossary, where appropriate.

Carried Interest   Carried interest is equivalent to a performance fee. This represents a share of the profits that will accrue to the underlying private equity managers, after achievement of an agreed Preferred Return.
Cash drag   Cash drag is the negative impact on performance arising as a result of the allocation of a portion of the entity’s assets to cash.
Co-investment   Co-investment is a Direct Investments in a company alongside a private equity fund.
Co-investment Incentive Scheme Accrual   Co-investment Incentive Scheme Accrual represents the estimated value of interests in the Co-investment Incentive Scheme operated by the subsidiary partnerships of the Company.
Commitment   Commitment represents the amount of capital that each investor agrees to contribute to a fund or a specific investment.
Compound Annual Growth Rate CAGR The rate of return that would be required for an investment to grow from its beginning balance to its ending balance, assuming the profits were reinvested at the end of each period of the investment’s life span.
Deployment   Please see ‘Total new investment’.
Direct Investments   An investment in a portfolio company held directly, not through a private equity fund. Direct Investments are typically co-investments with a private equity fund.
Discount   Discount arises when the Company’s shares trade at a price below the Company’s NAV per Share. In this circumstance, the price that an investor pays or receives for a share would be less than the value attributable to it by reference to the underlying assets. The Discount is the difference between the share price and the NAV, expressed as a percentage of the NAV. For example, if the NAV was 100p and the share price was 90p, the Discount would be 10%.
Dividend   Dividend is a distribution of a portion of a Company’s earnings to its shareholders. Dividends are usually paid in cash, and are determined by the Company’s board of directors.
Drawdowns   Drawdowns are amounts invested by the Company when called by underlying managers in respect of an existing Commitment.
EBITDA   Stands for earnings before interest, tax, depreciation and amortisation, which is a widely used performance measure in the private equity industry.
Enlarged Perimeter   As well as performance metrics for our Top 30 companies, we include data for our “Enlarged Perimeter”, which represents the aggregate value of the Top 30 Companies and as many of the managers from within the Top 30 funds as practicable.
Enterprise Value EV Enterprise Value is the aggregate value of a company’s entire issued share capital and Net Debt.
Exclusion List   The Exclusion List defines the business activities which are excluded from investment.
FTSE All-Share Index Total Return   The change in the level of the FTSE All-Share Index, assuming that dividends are re-invested on the day that they are paid.
Full Exits   Full Exits are exit events (e.g., trade sale, sale by public offering, or sale to a financial buyer) following which the residual exposure to an underlying company is zero or immaterial; this does not include Fund Disposals. See ‘Fund Disposals’.
Fund Disposals   Fund Disposals are where the Company receives sales proceeds from the full or partial sale of a fund position within the secondary market.
General Partner GP The General Partner is the entity managing a private equity fund. This is commonly referred to as the manager.
Hedging   Hedging is an investment technique designed to offset a potential loss on one investment by purchasing a second investment that is expected to perform in the opposite way.
Initial Public Offering IPO An Initial Public Offering is an offering by a company of its share capital to the public with a view to seeking an admission of its shares to a recognised stock exchange.
Internal Rate of Return IRR Internal Rate of Return is a measure of the rate of return received by an investor in a fund. It is calculated from cash drawn from and returned to the investor, together with the residual value of the investment.
Investment Period   Investment Period is the period in which funds are able to make new investments under the terms of their fund agreements, typically up to five years after the initial Commitment.
Last Twelve Months LTM Last Twelve Months refers to the timeframe of the immediately preceding 12 months in reference to financial metrics used to evaluate the Company’s performance.
Limited Partner

LP The Limited Partner is an institution or individual who commits capital to a private equity fund established as a Limited Partnership. These funds are generally protected from legal actions and any losses beyond the original investment.
Limited Partnership

  A Limited Partnership includes one or more General Partners, who have responsibility for managing the business of the partnership and have unlimited liability, and one or more Limited Partners, who do not participate in the operation of the partnership and whose liability is ordinarily capped at their capital and loan contribution to the partnership. In typical fund structures, the General Partner receives a priority share ahead of distributions to Limited Partners.

Net Asset Value per Share NAV per Share Net Asset Value per Share is the value of the Company’s net assets attributable to one Ordinary share. It is calculated by dividing ‘shareholders’ funds’ by the total number of ordinary shares in issue. Shareholders’ funds are calculated by deducting current and long-term liabilities, and any provision for liabilities and charges, from the Company’s total assets.
Net Debt   Net Debt is calculated as the total short-term and long-term debt in a business, less cash and cash equivalents.
Ongoing Charges   Ongoing Charges are calculated in line with guidance issued by the Association of Investment Companies (‘AIC’) and capture management fees and expenses, excluding finance costs, incurred at the Company level only. The calculation does not include the expenses and management fees incurred by any underlying funds.
Other Net Liabilities   Other Net Liabilities at the aggregated Company level represent net other liabilities per the Company’s balance sheet. Net other liabilities per the balance sheet of the subsidiaries include amounts payable under the Co-investment Incentive Scheme Accrual.
Overcommitment   Overcommitment refers to where private equity fund investors make Commitments exceeding the amount of cash immediately available for investment. When determining the appropriate level of Overcommitment, careful consideration needs to be given to the rate at which Commitments might be drawn down, and the rate at which realisations will generate cash from the existing Portfolio to fund new investment.

Portfolio   Portfolio represents the aggregate of the investment Portfolios of the Company and of its subsidiary Limited Partnerships. This APM is consistent with the commentary in previous annual and interim reports. The Board and the Manager consider that disclosing our Portfolio assists shareholders in understanding the value and performance of the underlying investments selected by the Manager. It is shown before the Co-investment Incentive Scheme Accrual to avoid being distorted by certain funds and Direct Investments on which ICG Enterprise Trust Plc does not incur these costs (for example, on funds managed by ICG plc). Portfolio is related to the NAV, which is the value attributed to our shareholders, and which also incorporates the Co-investment Incentive Scheme Accrual as well as the value of cash and debt retained on our balance sheet.
The value of the Portfolio at 31 July 2026 is £1,382.9m (31 July 2025: £1,415.6m).
     
    31 July 2026 £m IFRS balance sheet fair value Net assets of subsidiary limited partnerships Co-investment Incentive Scheme Accrual Total Company and subsidiary Limited Partnership      
    Investments1 1,341.6 (0.4) 41.6 1,382.9      
    Cash 19.4 — — 19.4      
    Other Net Liabilities (89.1) 0.4 (41.6) (130.3)      
    Net assets 1,271.9 — — 1,271.9      
                   
    31 July 2025 £m IFRS balance sheet fair value Balances receivable from subsidiary Limited Partnerships

Co-investment Incentive Scheme Accrual Total Company and subsidiary Limited Partnership      
    Investments1 1,361.5 (0.4) 54.4 1,415.6      
    Cash 20.9 — — 20.9      
    Other Net Liabilities (96.1) 0.4 (54.4) (150.1)      
    Net assets 1,286.3 — — 1,286.3      
    1Investments as reported on the IFRS balance sheet at fair value comprise the total of assets held by the Company and the net asset value of the Company’s investments in the subsidiary Limited Partnerships.      
             
Portfolio Return on a Local Currency Basis   Portfolio Return on a Local Currency Basis represents the change in the valuation of the Company’s Portfolio before the impact of currency movements and the Co-investment Incentive Scheme Accrual. The Portfolio return is calculated as follows:      
      £m 31 July 2026 31 July 2025      
    Income, gains and losses on Investments   34.2 64.2      
    Foreign exchange (losses) and gains included in losses and gains on investments   5.6 (30.1)      
    Incentive accrual valuation movement   3.3 (2.4)      
    Total gains on Portfolio investments excluding impact of foreign exchange   43.1 31.7      
    Opening Portfolio valuation   1,352.9 1,523.1      
    Portfolio Return on a Local Currency Basis   3.2% 2.1%      
                   

Term Short form Definition
Portfolio Company   Portfolio Company refers to an individual company in an investment portfolio.
Premium   Premium occurs when the share price is higher than the NAV and investors would therefore be paying more than the value attributable to the shares by reference to the underlying assets.
Primary Investment   A Primary Investment is a Commitment to a private equity fund.
Quoted Company   A Quoted Company is any company whose shares are listed or traded on a recognised stock exchange.
Realisation Proceeds

  Realisation Proceeds are amounts received in respect of underlying realisation activity from the Portfolio and exclude any inflows from the sale of fund positions via the secondary market.
Realisations – Multiple to Cost

  Multiple of Cost is the average return since inception on Full Exits from the Portfolio during the period, weighted by cost. It compares total cumulative proceeds, including proceeds received in prior periods, with the original cost of each investment. The calculation excludes publicly listed companies exited through share sell-downs
    Of Full Exits in the period (£m)   31 July 2026 31 July 2025
    Realisation Proceeds in the period   55.0 62.1
    Realisation Proceeds received in prior periods   15.4 7.9
    Realisation Proceeds from inception   70.4 70.0
    Cost from inception   23.3 23.8
    Average total Multiple to Cost   3.0x 2.9x
Realisations – Uplift To Carrying Value   Uplift to Carrying Value is the aggregate uplift on Full Exits from the Portfolio during the period. It compares Realisation Proceeds to the most recent valuation prior to the announcement of the disposal. The calculation excludes publicly listed companies that were exited via sell downs of their shares
    £m   31 July 2026 31 July 2025
    Uplift on Prior Carrying Value   5.6 7.9
    Prior Carrying Value (most recent valuation prior to the announcement of the disposal)   59.7 58.5
    Realisations – Uplift To Carrying Value   9.4% 13.5%
Secondary Investments   Secondary Investments occur when existing private equity fund interests and Commitments are purchased from an investor seeking liquidity.
Share buyback   Share buybacks, or stock repurchases, occur when a company uses its own funds to buy its outstanding shares in the open market, thereby reducing the number of shares in circulation. As a result of buybacks, existing shareholders own a greater percentage of the company’s assets and profits. If share buybacks are executed at a discount to NAV, the buyback will increase the NAV per Share of the remaining shares outstanding.
Share Price Total Return   Share Price Total Return is the change in the Company’s share price, assuming that dividends are re-invested on the day that they are paid.
Total New Investment   Total New Investment is the total of direct Co-investment and fund investment Drawdowns in respect of the Portfolio. In accordance with IFRS 10, the Company’s subsidiaries are deemed to be investment entities and are included in subsidiary investments within the financial statements.

Movements in the cash flow statement within the financial statements reconcile to the movement in the Portfolio as follows:

    £m   31 July 2026 31 July 2025
    Purchase of Portfolio investments per cash flow statement   18.6 17.5
    Purchase of Portfolio investments within subsidiary investments   52.5 101.2
    Return of cost/expenses   (6.1) (5.6)
    Total New Investment   65.0 113.1
           

Term Short form Definition        
Total Proceeds   Total Proceeds are amounts received by the Company in respect of the Portfolio, which may be in the form of capital proceeds or income such as interest or dividends. In accordance with IFRS 10, the Company’s subsidiaries are deemed to be investment entities and are included in subsidiary investments within the financial statements.
    £m     31 July 2026 31 July 2025
    Sale of Portfolio investments per cash flow statement     14.6 42.4
    Sale of Portfolio investments, interest received, and dividends received within subsidiary investments     69.1 179.2
    Interest income per cash flow statement     0.0 0.2
    Dividend income per cash flow statement     0.1 0.3
    Other income per cash flow statement     0.1 0.2
    Return of invested cost     (0.1) 3.8
    Deal costs arising from Secondary Sales     0.0 (3.9)
    Total Proceeds     83.8 222.2
    Fund Disposals     0.0 (66.3)
    Realisation Proceeds     83.8 155.9
Total Return   The change in the Company’s Net Asset Value per Share, assuming that dividends are re-invested at the
end of the quarter in which the dividend was paid.
Undrawn Commitments   Undrawn Commitments are Commitments that have not yet been drawn down (please see ‘Drawdowns’).
Unquoted Company   An Unquoted Company is any company whose shares are not listed or traded on a recognised stock exchange.
Valuation Date   The date of the valuation report issued by the underlying manager.
Valuation Multiples   Valuation Multiples are earnings (EBITDA), or revenue multiples applied in determining the value of a business enterprise.

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

Neuberger Private Equity Partners Announces Transaction in Own Shares

St Peter Port, Guernsey 7 October 2026

Neuberger Private Equity Partners Limited (“NBPE” or the “Company”) today announces details of Class A Shares bought back pursuant to general authority granted by shareholders of the Company on 11 June 2026 and the share buy-back agreement with Jefferies International Limited.

Transaction on London Stock Exchange

Date of purchase of Shares 6 October 2026
Number of Shares purchased 30,001 Class A Shares
Highest price/lowest price paid £15.02 / £14.96
ISIN for the Shares GG00B1ZBD492

All Class A Shares bought back will be cancelled. Following the cancellation, the number of outstanding Class A Shares is 37,461,206‬. The Company also has 3,150,408 Class A shares held in treasury. For reporting purposes under the FCA’s Disclosure Guidance and Transparency Rules the market should use the figure of 37,461,206 voting rights when determining if they are required to notify their interest in, or a change to their interest in the Company.

For further information, please contact:

NBPE Investor Relations        +44 20 3214 9002
Luke Mason        NBPrivateMarketsIR@nb.com

Oak Group        +44 1481 723450

        NBPEP@oak.group

About Neuberger Private Equity Partners Limited

Neuberger Private Equity Partners Limited (“NBPE”) invests in direct private equity investments alongside market leading private equity firms globally. NB Alternatives Advisers LLC (the “Investment Manager”), an indirect wholly owned subsidiary of Neuberger Berman Group LLC, is responsible for sourcing, execution and management of NBPE. The vast majority of direct investments are made with no management fee / no carried interest payable to third-party GPs, offering greater fee efficiency than other listed private equity companies. NBPE seeks capital appreciation through growth in net asset value over time while paying a bi-annual dividend.

LEI number: 213800UJH93NH8IOFQ77

About Neuberger

Neuberger was founded in 1939 to do one thing: deliver compelling investment results for our clients over the long term. This remains our singular purpose today, driven by a culture rooted in deep fundamental research, the pursuit of investment insight and continuous innovation on behalf of clients, and facilitated by the free exchange of ideas across the organization.

From offices in 39 cities[1] across 26 countries, Neuberger manages a range of equity, fixed income, private equity and hedge fund strategies on behalf of institutions, advisors and individual investors worldwide. With more than 780[1] investment professionals and over 2,900[1] employees in total, Neuberger has built a diverse team of individuals united in their commitment to client outcomes and investment excellence. Our culture has afforded us enviable retention rates among our senior investment staff and we are proud to have been ranked 1st by Pensions & Investments in their 2025 “Best Places to Work in Money Management” survey, where we have placed 1st in four of the last five years and finished in the top two for 12 consecutive years[2].

As a private, independent, employee-owned investment manager, Neuberger is structurally aligned with the long-term interests of our clients. We have no external parent or public shareholders to serve, nor other lines of business to distract us from our core mission. And with our employees and their families invested alongside our clients—plus 100% of employee deferred cash compensation directly linked to team and firm strategies—we are truly in this together.
For more information, please visit our website: www.nb.com/en/global/who-we-are.

Media Contacts:
US: Soogyung Jordan: Soogyung.Jordan@nb.com
EMEA: Fiona Kehily: Fiona.Kehily@nb.com

[1] Firm data reflects the collective data for the various subsidiaries of Neuberger Berman Group LLC as of 30 June 2026.

[2] Among organizations with over 1,000 employees by Pensions & Investments. For additional information on the criteria for the award, please visit https://www.pionline.com/awards/best-places-to-work-in-money-management/pi-best-places-to-work-2025.

This material is issued on a limited basis through various global subsidiaries and affiliates of Neuberger Berman Group LLC. Please visit www.nb.com/disclosure-global-communications to learn about each company and the legal restrictions and restrictions. The name “Neuberger Berman” and logo are registered service marks of Neuberger Berman Group LLC.

© 2026 Neuberger Berman Group LLC. All rights reserved.

This press release appears as a matter of record only and does not constitute an offer to sell or a solicitation of an offer to purchase any security.

NBPE is established as a closed-end investment company domiciled in Guernsey. NBPE has received the necessary consent of the Guernsey Financial Services Commission. The value of investments may fluctuate. Results achieved in the past are no guarantee of future results. This document is not intended to constitute legal, tax or accounting advice or investment recommendations. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. Statements contained in this document that are not historical facts are based on current expectations, estimates, projections, opinions and beliefs of NBPE’s investment manager. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. Additionally, this document contains “forward-looking statements.” Actual events or results or the actual performance of NBPE may differ materially from those reflected or contemplated in such targets or forward-looking statements.

The following is an update to the third quarter 2026 outlook and gives an overview of our current expectations for the third quarter. Outlooks presented may vary from the actual third quarter 2026 results and are subject to finalisation of those results, which are scheduled to be published on 29 October, 2026. Unless otherwise indicated, all outlook statements exclude identified items. 

See appendix for the definition of the non-GAAP measure used, the reconciliation from GAAP to non-GAAP and the most comparable GAAP measure.

   Integrated Gas

$ billions Q2’26 Q3’26 Outlook Comment
Production (kboe/d) 631 740 – 780  
LNG liquefaction volumes (MT) 7.7 7.2 – 7.6  
Underlying opex 1.1 1.3 – 1.5  
Pre-tax depreciation 1.2 1.1 – 1.5  
Taxation charge 0.8 0.6 – 0.9  
Other Considerations:
Trading & Optimisation is expected to be in line with Q2’26.
Outlook includes the acquisition of ARC resources, which completed on 2 September, 2026.

 Upstream

$ billions Q2’26 Q3’26 Outlook Comment
Production (kboe/d) 1,824 1,735 – 1,835  
Underlying opex 2.2 2.1 – 2.5  
Pre-tax depreciation 2.5 2.2 – 2.8  
Taxation charge 2.8 2.5 – 3.3  
Other Considerations:
Q3’26 exploration well write-offs are expected to be ~$0.3 billion.

 Marketing

$ billions Q2’26 Q3’26 Outlook Comment
Sales volumes (kb/d) 2,570 2,550 – 2,650  
Underlying opex 2.5 2.3 – 2.7  
Pre-tax depreciation 0.6 0.5 – 0.7  
Taxation charge 0.4 0.2 – 0.5  
Other Considerations:
Marketing adjusted earnings are expected to be lower than Q2’26.

  Chemicals and Products

$ billions Q2’26 Q3’26 Outlook Comment
Indicative refining margin* $24/bbl $42/bbl  
Indicative chemicals margin* $270/tonne $208/tonne  
Refinery utilisation 102% 93% – 97% Low Rhine water levels impacting Rheinland refinery utilisation.
Chemicals utilisation 83% 81% – 85%  
Underlying opex 1.9 1.7 – 2.1  
Pre-tax depreciation 1.1 1.1 – 1.3  
Taxation charge / (credit) 0.6 1.0 – 1.5  
Other Considerations:
Trading & Optimisation is expected to be in line with Q2’26.

*See appendix

 Renewables and Energy Solutions

$ billions Q2’26 Q3’26 Outlook Comment
Adjusted Earnings 0.1 0.0 – 0.4  

  

Corporate

$ billions Q2’26 Q3’26 Outlook Comment
Adjusted Earnings (0.6) (0.8) – (0.6)  

Shell Group

$ billions Q2’26 Q3’26 Outlook Comment
CFFO:
Tax paid 2.9 3.1 – 3.9  
Financial Derivative Instruments movements (0.4) 0 – 5  
Other 0.1 (4) – 1 CFFO excluding working capital is expected to include an ~$2.5 billion outflow related to timing of payments of emissions certificates relating to the German BEHG*. 
Working capital 3.4 (4) – 1  
Other Shell Group Considerations:
CFFO excluding working capital includes a $0.8 billion JV dividend inflow, which is offset by a $0.8 billion outflow through working capital (as funds were previously held in deposit by the corporate segment). The net impact on CFFO is zero.
Non-cash post tax impairments of biogas assets in Marketing are expected to be largely offset by an impairment reversal in Integrated Gas. Both are reported as identified items.
Net debt will be impacted by ARC acquisition cash consideration & assumption of debt and an increase in variable components of long-term shipping leases in the current macro environment.

*Brennstoffemissionshandelsgesetz (Fuel Emissions Trading Act), historically paid in the 4th quarter of each calender year

Guidance

The ‘Quarterly Databook’ contains guidance on Indicative Refining Margin, Indicative Chemicals Margin and full-year price and margin sensitivities.

Consensus

The company compiled consensus, managed by Vara Research, is expected to be published on October 21, 2026.

Appendix

Indicative Margins

Chemicals & Products Q2’26 Q3’26 Updated Outlook
Indicative refining margin $24/bbl $42/bbl
Indicative chemicals margin $270/tonne $208/tonne

Volume Data

Operational Metrics Q2’26 Q3’26 QPR Outlook Q3’26 Updated Outlook
Integrated Gas      
Production (kboe/d) 631 570 – 630* 740 – 780
LNG liquefaction volumes (MT) 7.7 7.1 – 7.7 7.2 – 7.6
Upstream      
Production (kboe/d) 1,824 1,680 – 1,880 1,735 – 1,835
Marketing      
Sales volumes (kb/d) 2,570 2,550 – 2,750 2,550 – 2,650
Chemicals & Products      
Refinery utilisation 102% 93% – 101% 93% – 97%
Chemicals utilisation 83% 78% – 86% 81% – 85%

*Q3’26 QPR production outlook excluded volumes from ARC Resources and Qatar.

Underlying Opex

Underlying operating expenses is a measure aimed at facilitating a comparative understanding of performance from period to period by removing the effects of identified items, which, either individually or collectively, can cause volatility, in some cases driven by external factors. Underlying operating expenses comprises the following items from the Consolidated statement of Income: production and manufacturing expenses; selling, distribution and administrative expenses; and research and development expenses and removes the effects of identified items such as redundancy and restructuring charges or reversals, provisions or reversals and others. For further details see the 2nd Quarter 2026 and half year unaudited results.

$ billions Q2’26 Q2’26 Adjusted Q3’26 Updated Outlook
Production and manufacturing expenses 5.5    
Selling, distribution and administrative expenses 2.9    
Research and development 0.3    
Operating Expenses (Opex) 8.7 8.7  
Less: Identified Items   0.2  
Underlying Opex   8.4  
    of which:      
    Integrated Gas 1.1 1.1 1.3 – 1.5
    Upstream 2.2 2.2 2.1 – 2.5
    Marketing 2.5 2.5 2.3 – 2.7
    Chemicals and Products 2.0 1.9 1.7 – 2.1
    Renewables and Energy Solutions 0.6 0.6  

Depreciation, depletion and amortisation

$ billions Q2’26 Q2’26 Adjusted Q3’26 Updated Outlook
Depreciation, Depletion & Amortisation 6.2 6.2  
Less: Identified Items   0.6  
Pre-tax depreciation (as Adjusted)   5.6  
    of which:      
    Integrated Gas 1.2 1.2 1.1 – 1.5
    Upstream 2.5 2.5 2.2 – 2.8
    Marketing 0.6 0.6 0.5 – 0.7
    Chemicals and Products 1.2 1.1 1.1 – 1.3
    Renewables and Energy Solutions 0.7 0.1  

Taxation Charge

$ billions Q2’26 Q2’26 Adjusted Q3’26 Updated Outlook
Taxation Charge 4.9 4.9  
Less: Identified Items and Cost of supplies adjustment   0.4  
Taxation Charge (as Adjusted)   4.5  
    of which:      
    Integrated Gas 0.8 0.8 0.6 – 0.9
    Upstream 2.7 2.8 2.5 – 3.3
    Marketing 0.7 0.4 0.2 – 0.5
    Chemicals and Products 1.0 0.6 1.0 – 1.5
    Renewables and Energy Solutions (0.1) —  

Adjusted Earnings

The “Adjusted Earnings” measure aims to facilitate a comparative understanding of Shell’s financial performance from period to period by removing the effects of oil price changes on inventory carrying amounts and removing the effects of identified items. These items are in some cases driven by external factors and may, either individually or collectively, hinder the comparative understanding of Shell’s financial results from period to period. This measure excludes earnings attributable to non-controlling interest. For further details see the 2nd Quarter 2026 and half year unaudited results.

$ billions Q2’26 Q2’26 Adjusted Q3’26 Updated Outlook
Income/(loss) attributable to Shell plc shareholders 10.8 10.8  
Add: Current cost of supplies adjustment attributable to Shell plc shareholders   (0.6)  
Less: Identified items attributable to Shell plc shareholders   0.4  
Adjusted Earnings   9.8  
    of which:      
    Renewables and Energy Solutions (0.6) 0.1 0.0 – 0.4
    Corporate (0.6) (0.6) (0.8) – (0.6)

Working Capital

Working capital movements are defined as the sum of the following items in the Consolidated Statement of Cash Flows: (i) (increase)/decrease in inventories, (ii) (increase)/decrease in current receivables, and (iii) increase/(decrease) in current payables.

Net Debt

Net debt is defined as the sum of current and non-current debt, less cash and cash equivalents, adjusted for the fair value of derivative financial instruments used to hedge foreign exchange and interest rate risks relating to debt, and associated collateral balances.

Enquiries

Media International: +44 (0) 207 934 5550

Media U.S. and Canada: Contact form

Cautionary Note

The companies in which Shell plc directly and indirectly owns investments are separate legal entities. In this announcement “Shell”, “Shell Group” and “Group” are sometimes used for convenience to reference Shell plc and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Shell plc and its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. ‘‘Subsidiaries’’, “Shell subsidiaries” and “Shell companies” as used in this announcement refer to entities over which Shell plc either directly or indirectly has control. The terms “joint venture”, “joint operations”, “joint arrangements”, and “associates” may also be used to refer to a commercial arrangement in which Shell has a direct or indirect ownership interest with one or more parties.  The term “Shell interest” is used for convenience to indicate the direct and/or indirect ownership interest held by Shell in an entity or unincorporated joint arrangement, after exclusion of all third-party interest.

The numbers presented in this announcement may not sum precisely to the totals provided and percentages may not precisely reflect the absolute figures due to rounding.

Forward-Looking statements
This announcement contains forward-looking statements (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995) concerning the financial condition, results of operations and businesses of Shell. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions, including (without limitation) those concerning Shell’s strategy and operating plans, macroeconomic conditions, future energy demand, supply and product mix, commodity prices, demand for Shell’s products, production results and reserve estimates, development, execution and management of projects, energy transition and climate change, management of safety and environmental risks, costs, cash capital expenditures, technology advancements, legislative, judicial, fiscal and regulatory developments, regional conflicts and trading conditions, and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include, among other things, statements concerning the potential exposure of Shell to market risks and statements expressing management’s expectations, beliefs, estimates, forecasts, projections and assumptions. These forward-looking statements are identified by their use of terms and phrases such as “aim”; “ambition”; ‘‘anticipate’’; “aspire”; “aspiration”; ‘‘believe’’; “commit”; “commitment”; ‘‘could’’; “desire”; ‘‘estimate’’; ‘‘expect’’; ‘‘goals’’; ‘‘intend’’; ‘‘may’’; “milestones”; ‘‘objectives’’; ‘‘outlook’’; ‘‘plan’’; ‘‘probably’’; ‘‘project’’; ‘‘risks’’; “schedule”; ‘‘seek’’; ‘‘should’’; ‘‘target’’; “vision”; ‘‘will’’; “would” and similar terms and phrases. There are a number of factors that could affect the future operations of Shell and could cause those results to differ materially from those expressed in the forward-looking statements included in this announcement, including (without limitation): (a) price fluctuations in crude oil and natural gas; (b) changes in demand for Shell’s products; (c) currency fluctuations; (d) drilling and production results; (e) reserves estimates; (f) loss of market share and industry competition; (g) environmental and physical risks, including climate change; (h) risks associated with the identification of suitable potential acquisition properties and targets, and successful negotiation and completion of such transactions; (i) the risk of doing business in developing countries and countries subject to international sanctions; (j) legislative, judicial, fiscal and regulatory developments including tariffs and regulatory measures addressing climate change; (k) economic and financial market conditions in various countries and regions; (l) political risks, including the risks of expropriation and renegotiation of the terms of contracts with governmental entities, delays or advancements in the approval of projects and delays in the reimbursement for shared costs; (m) risks associated with the impact of pandemics, regional conflicts, such as the Russia-Ukraine war and the conflict in the Middle East, and a significant cyber security, data privacy or IT incident; (n) the pace of the energy transition; and (o) changes in trading conditions. No assurance is provided that future dividend payments will match or exceed previous dividend payments. All forward-looking statements contained in this announcement are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Additional risk factors that may affect future results are contained in Shell plc’s Form 20-F for the year ended December 31, 2025 (available at www.shell.com/investors/news-and-filings/sec-filings.html and www.sec.gov). These risk factors also expressly qualify all forward-looking statements contained in this announcement and should be considered by the reader. Each forward-looking statement speaks only as of the date of this announcement, October 7, 2026. Neither Shell plc nor any of its subsidiaries undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. In light of these risks, results could differ materially from those stated, implied or inferred from the forward-looking statements contained in this announcement.

Shell’s net carbon intensity and net-zero emissions target
In this announcement we may refer to Shell’s “net carbon intensity” (NCI), which includes Shell’s carbon emissions from the production of our energy products, our suppliers’ carbon emissions in supplying energy for that production and our customers’ carbon emissions associated with their use of the energy products we sell. Shell’s NCI also includes the emissions associated with the production and use of energy products produced by others which Shell purchases for resale. Shell only controls its own emissions. The use of the terms Shell’s “net carbon intensity” or NCI is for convenience only and not intended to suggest these emissions are those of Shell plc or its subsidiaries.

Shell’s operating plan and outlook are forecasted for a three-year period and ten-year period, respectively, and are updated every year. They reflect the current economic environment and what we can reasonably expect to see over the next three and ten years. Accordingly, the outlook reflects our combined Scope 1 and 2 target, NCI targets and our oil products ambition over the next ten years. However, Shell’s operating plan and outlook cannot reflect our 2050 net-zero emissions target, as this target is outside our planning period. Such future operating plans and outlooks could include changes to our portfolio, efficiency improvements and the use of carbon capture and storage and carbon credits. In the future, as society moves towards net-zero emissions, we expect Shell’s operating plans and outlooks to reflect this movement. However, if society is not net zero in 2050, as of today, there would be significant risk that Shell may not meet this target.

The information provided above regarding Shell’s NCI and net zero emissions target are not intended, nor should they be construed as introducing, suggesting or making any claim, target or representation thereof other than what is included in the announcement.

Forward-Looking Non-GAAP measures

This announcement may contain certain forward-looking non-GAAP measures such as Adjusted Earnings, Cash flow from operating activities excluding working capital movements, Net debt and Underlying operating expense.

We are unable to provide a reconciliation of these forward-looking non-GAAP measures to the most comparable GAAP financial measures because certain information needed to reconcile those non-GAAP measures to the most comparable GAAP financial measures is dependent on future events some of which are outside the control of Shell, such as oil and gas prices, interest rates and exchange rates. Moreover, estimating such GAAP measures with the required precision necessary to provide a meaningful reconciliation is extremely difficult and could not be accomplished without unreasonable effort. Non-GAAP measures in respect of future periods which cannot be reconciled to the most comparable GAAP financial measure are calculated in a manner which is consistent with the accounting policies applied in Shell plc’s consolidated financial statements. These forward-looking non-GAAP measures are provided to assist readers in understanding management’s use and expectations of such measures and may not be appropriate for other purposes. 

The contents of websites referred to in this announcement do not form part of this announcement.

We may have used certain terms, such as resources, in this announcement that the United States Securities and Exchange Commission (SEC) strictly prohibits us from including in our filings with the SEC. Investors are urged to consider closely the disclosure in our Form 20-F, File No 1-32575, available on the SEC website www.sec.gov.

7 October 2026

Transaction in own shares

Admiral Group plc (the “Company”) announces that for the period 30 September 2026 to 6 October 2026 it has purchased for cancellation 250,000 of its ordinary shares of 0.1 pence each (‘ordinary shares’), as detailed below, through the Company’s broker UBS AG, London Branch (“UBS“) as part of its buy-back announced on 30 September 2026.

Date of Purchase Aggregate number of ordinary shares purchased Volume weighted average price (GB pence) Highest Price per share (GB pence) Lowest Price per share (GB pence) Trading venue
30 September 2026 22,000 3,647.5156 3,686.00 3,620.00 London Stock Exchange
30 September 2026 19,000 3,642.0444 3,684.00 3,620.00 BATS Europe
30 September 2026 6,000 3,642.8340 3,680.00 3,622.00 Chi-X Europe
30 September 2026 3,000 3,643.1220 3,674.00 3,622.00 Aquis
01 October 2026 22,126 3580.7399 3596.00 3554.00 London Stock Exchange
01 October 2026 18,874 3579.9839 3596.00 3558.00 BATS Europe
01 October 2026 6,000 3580.2047 3592.00 3564.00 Chi-X Europe
01 October 2026 3,000 3580.6727 3592.00 3564.00 Aquis
02 October 2026 22,737 3,600.4567 3,632.00 3,580.00 London Stock Exchange
02 October 2026 18,442 3,598.0853 3,632.00 3,574.00 BATS Europe
02 October 2026 5,821 3,597.7007 3,624.00 3,578.00 Chi-X Europe
02 October 2026 3,000 3,597.3713 3,624.00 3,576.00 Aquis
05 October 2026 22,125 3601.6494 3622.00 3576.00 London Stock Exchange
05 October 2026 18,913 3602.7581 3622.00 3576.00 BATS Europe
05 October 2026 5,667 3602.9642 3626.00 3580.00 Chi-X Europe
05 October 2026 3,295 3602.7781 3616.00 3574.00 Aquis
06 October 2026 22,084 3616.5730 3658.00 3590.00 London Stock Exchange
06 October 2026 19,013 3616.5150 3656.00 3592.00 BATS Europe
06 October 2026 5,617 3616.6028 3656.00 3588.00 Chi-X Europe
06 October 2026 3,286 3615.6762 3654.00 3594.00 Aquis

The Company intends to cancel all of the purchased ordinary shares.

Following the cancellation of the repurchased shares reported above, the Company’s issued share capital will consist of 306,054,676 ordinary shares with voting rights.

There are no ordinary shares held in Treasury.

The above figure (306,054,676) may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company’s under the FCA’s Disclosure Guidance and Transparency Rules.

From the commencement of the share buy-back programme on 30 September 2026, the Company has purchased 250,000 ordinary shares in aggregate at a weighted average price of 3,608.57p per ordinary share.

In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended, a full breakdown of the individual purchases of ordinary shares made by UBS on behalf of the Company can be found in the link to this announcement.

Schedule of purchases – 30.06.26 – 06.10.26

– ENDS –

For further information, please contact:

Media:        
Sian Broad                                sian.broad5@admiralgroup.co.uk         

Investors/ Analysts:        
Jelena Bjelanovic                        investorrelationssupport@admiralgroup.co.uk

Attachment

SINGAPORE, Oct. 07, 2026 (GLOBE NEWSWIRE) — Valeura Energy Inc. (TSX:VLE, OTCQX:VLERF) (“Valeura” or the “Company”) provides an operations and financial update for Q3 2026.

Highlights

  • Oil production averaged 22.1 mbbls/d(1);
  • Sales of 2.013 million bbls;
  • Price realisations averaged US$97.4/bbl, resulting in revenue of US$196.1 million;
  • Cash position of US$384.9 million at 30 September 2026(2) and no debt;
  • Exploration discovery on Block G1/48(3) – the Suraphi oil field;
  • Final investment decision on the first phase of development of the Bussabong gas field, on Block G3/65(4);
  • Milestone cumulative production of 100 million bbls of oil from the Jasmine field as of 21 September 2026(5); and
  • Early completion of onshore construction of the Wassana central processing platform (“CPP”), on track for accelerated installation in the field in Block G10/48(6), starting in October 2026.

(1) Working interest share production, before royalties.
(2) Includes restricted cash of US$15.8 million.
(3) Block G1/48, 90% operated working interest.
(4) Block G3/65, 40% non-operated working interest; Thailand’s cabinet has granted executive approval for the assignment of interest to Valeura. Completion anticipated in October 2026.
(5) Block B5/27, 100% operated interest.
(6) Block G10/48, 100% operated interest.

Dr. Sean Guest, President and CEO commented:
“Our Q3 2026 production was exactly on plan, and once again, confirms our guidance expectations for the full year 2026. Operational performance has been very strong, with no deviations from our high standards on health, safety, and environmental stewardship. At the same time, our financial performance has been remarkable as the Company is able to capture full benefit of current oil prices as it carries no hedging, operates under simple tax/royalty-based fiscal terms, and benefits from historic tax loss carry-forwards. Our balance sheet is stronger than ever before, with US$385 million in cash and no debt.

During Q3, we advanced several strategic priorities including securing government approval for our Block G1/65 and G3/65 farm-in(1), and thereafter taking a final investment decision to pursue the first phase of gas development on the Bussabong field. We are also encouraged by the potential for additional oil development on Block G1/48 as a result of our exploration discovery of the Suraphi field, which we believe has the potential to extend the productive life of the Manora field and may support further exploration and development opportunities in the area.

We also achieved a key milestone at our Jasmine field this quarter, with cumulative production hitting the milestone of 100 million barrels of oil produced to date. More recently, our Wassana redevelopment project achieved a key milestone as well. Onshore construction of our new-build CPP was completed early and is on track for accelerated installation, starting in October 2026.

Operationally and financially, our business is delivering extremely well and I am pleased to see external recognition of this across all aspects of our business. This quarter we were recognised by the Toronto Stock Exchange as one of the top 30 performing companies based on three-year share price performance. We received four awards from the Thailand Ministry of Environment for our environmental monitoring practices. And finally, our Company’s approach to adopting new technology was recognised by the Society of Petroleum Engineers in Thailand in response to our introduction of complex multi-lateral drilling at the Nong Yao field. ”

(1) 40% non-operated working interest.

Q3 2026 Update
Valeura’s working interest share production before royalties was on plan for Q3 2026, averaging 22.1 mbbls/d. The Company sold a total of 2.013 million bbls of oil during the quarter with average realised prices of US$97.4/bbl, resulting in revenue of US$196.1 million. Revenue includes crude oil receivables of US$22.5 million at 30 September 2026, in respect of oil sales just prior to the end of the quarter. The Company anticipates collecting upon such receivable in the early part of Q4 2026.

The Company’s cash position increased to US$384.9 million at 30 September 2026. Valeura has no debt.

Wassana CPP Completion
Onshore construction of the Wassana CPP was fully completed on 01 October 2026. Jacket and CPP have been loaded on to vessels for transportation and installation on the field, starting in October. This follows the installation of an oil export pipeline which will connect the new CPP to the floating storage and offloading vessel, which was completed in September, on plan and budget.    The Company is planning to begin development drilling late in 2026.  

Overall, the Company’s plan to accelerate the original Wassana redevelopment project schedule by approximately two months is on track. Management continues to forecast first oil production from the CPP at approximately the beginning of Q2 2027.

Results Timing
Valeura intends to release its full unaudited financial and operating results for Q3 2026 on 11 November 2026 and will discuss the results in more detail through a management webcast.

For further information, please contact:

Valeura Energy Inc. (General Corporate Enquiries)                +65 6373 6940
Sean Guest, President and CEO
Yacine Ben-Meriem, CFO
Contact@valeuraenergy.com  

Valeura Energy Inc. (Investor and Media Enquiries)                +1 403 975 6752
Robin James Martin, SVP, Communications and Investor Relations
IR@valeuraenergy.com

Contact details for the Company’s advisors, covering research analysts and joint brokers, including ATB Cormark Capital Markets, Auctus Advisors LLP, Beacon Securities Limited, Canaccord Genuity Ltd (UK), Research Capital Corporation, Roth Canada Inc., and Stifel Nicolaus Europe Limited, are listed on the Company’s website at www.valeuraenergy.com/investor-information/analysts/.

About the Company

Valeura Energy Inc. is a Canadian public company engaged in the exploration, development and production of petroleum and natural gas in Thailand and Türkiye. The Company is executing a growth-oriented strategy, reinvesting into its producing asset portfolio while deploying capital toward further organic and inorganic growth across Southeast Asia. Valeura is committed to delivering value-accretive growth for all stakeholders, underpinned by high standards of environmental, social and governance responsibility.

Additional information relating to Valeura is also available on SEDAR+ at www.sedarplus.ca.

Unaudited Financial Information

Certain anticipated financial and operating results for Q3 2026 in this news release are preliminary estimates based on unaudited financial information. These preliminary figures have not been audited or reviewed by the Company’s auditor and remain subject to change, which changes could be material, upon completion of the Company’s unaudited interim financial statements for the three and nine months ended 30 September 2026 and management’s final review.

Advisory and Caution Regarding Forward-Looking Information

Certain information included in this news release constitutes forward-looking information under applicable securities legislation. Such forward-looking information is for the purpose of explaining management’s current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes, such as making investment decisions. Forward-looking information typically contains statements with words such as “anticipate”, “believe”, “expect”, “plan”, “intend”, “estimate”, “propose”, “project”, “target” or similar words suggesting future outcomes or statements regarding an outlook. Forward-looking information in this news release includes, but is not limited to: the potential for more oil development on Block G1/48 as a result of the Company’s exploration discovery of the Suraphi field; and timing for the installation of the Wassana CPP, development drilling, and first oil production.    Forward-looking information is based on management’s current expectations and assumptions regarding, among other things: political stability of the areas in which the Company is operating and the continuity of existing fiscal and regulatory regimes; continued safety of operations and ability to proceed in a timely manner; continued operations of and approvals forthcoming from governments and regulators in a manner consistent with past conduct, including approval of gas pricing and formalization of gas sales agreements; future drilling activity on the required/expected timelines; the prospectivity of the Company’s lands; the continued favourable pricing and operating netbacks across its business; future production rates and associated operating netbacks and cash flow; decline rates; future sources of funding; future economic conditions; the impact of inflation on future costs; future currency exchange rates; interest rates; the ability to meet drilling deadlines and fulfil commitments under licences and leases; future commodity prices; the impact of geopolitical conflicts, including conflicts in the Middle East, and between Russia and Ukraine; royalty rates and taxes; future capital and other expenditures; the success obtained in drilling new wells and working over existing wellbores; the performance of wells and facilities; the availability of the required capital to fund its exploration, development and other operations, and the ability of the Company to meet its commitments and financial obligations; the ability of the Company to secure adequate processing, transportation, fractionation and storage capacity on acceptable terms, including access to processing facilities; the capacity and reliability of facilities; the application of regulatory requirements respecting abandonment and reclamation; the recoverability of the Company’s reserves and contingent resources; future growth; the sufficiency of budgeted capital expenditures in carrying out planned activities; the impact of increasing competition; the ability to efficiently integrate assets and employees acquired through acquisitions; global energy policies going forward; future debt levels; the Company’s continued ability to obtain and retain qualified staff and equipment in a timely and cost efficient manner; PTTEP’s continued participation as operator and joint venture partner in accordance with expectations; the timely completion of construction and deployment of wellhead platforms; and the continued applicability of customary Thai domestic gas pricing frameworks. In addition, the Company’s work programmes and budgets are in part based upon expected agreement among joint venture partners and associated exploration, development and marketing plans and anticipated costs and sales prices, which are subject to change based on, among other things, the actual results of drilling and related activity, availability of drilling, offshore storage and offloading facilities and other specialised oilfield equipment and service providers, changes in partners’ plans and unexpected delays and changes in market conditions. Although the Company believes the expectations and assumptions reflected in such forward-looking information are reasonable, they may prove to be incorrect.

Forward-looking information involves significant known and unknown risks and uncertainties. Exploration, appraisal, and development of oil and natural gas reserves and resources are speculative activities and involve a degree of risk. A number of factors could cause actual results to differ materially from those anticipated by the Company including, but not limited to: the ability of management to execute its business plan or realise anticipated benefits from the Farm-in and the Bussabong development, including the risk that actual capital expenditures exceed estimates or that development timelines are delayed; the risk of disruptions from public health emergencies and/or pandemics; competition for specialised equipment and human resources; the Company’s ability to manage growth; the Company’s ability to manage the costs related to inflation; disruption in supply chains; the risk of currency fluctuations; changes in interest rates, oil and gas prices and netbacks; potential changes in joint venture partner strategies and participation in work programmes; uncertainty regarding the contemplated timelines and costs for work programme execution; the risks of disruption to operations and access to worksites; potential changes in laws and regulations, the uncertainty regarding government and other approvals; counterparty risk; the risk that financing may not be available; risks associated with weather delays and natural disasters; geopolitical risks and instability; and the risk associated with international activity. See the Company’s most recent annual information form and the MD&A for a detailed discussion of the risk factors.

The forward-looking information contained in this news release is made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless required by applicable securities laws. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

This news release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction, including where such offer would be unlawful. This news release is not for distribution or release, directly or indirectly, in or into the United States, Ireland, the Republic of South Africa or Japan or any other jurisdiction in which its publication or distribution would be unlawful.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this news release.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

HOUSTON, Oct. 07, 2026 (GLOBE NEWSWIRE) — VAALCO Energy, Inc. (NYSE: EGY, LSE: EGY) (“Vaalco” or the “Company”) announced successful completion of the offshore Gabon Phase 3 drilling program, including encouraging initial well results on the ETSEM-3H well and demobilization of the rig from the SE Etame platform. Additionally, the Company provided updates on the recently commenced Baobab drilling program offshore Côte d’Ivoire.

Operational Highlights:

  • Offshore Gabon, successfully drilled, completed and placed on production the ETSEM-3H development well in an attic position within the SE Etame field, with a lateral wellbore of 300 meters of net pay in high-quality Gamba reservoir sands;
    • Achieved stabilized initial flow rate of approximately 2,000 gross barrels of oil per day (“BOPD”), 1,140 BOPD net to Vaalco;
    • Phase 3 drilling program is now complete; and
    • Drill rig (Borr Norve) has been demobilized from the field.
  • Offshore Côte d’Ivoire, the Baobab Phase 5 drilling operations have begun with the batch-setting of top-holes by the operator;
    • After the top-hole sections of all wells are drilled, the wells will then be completed and placed on production sequentially; and
    • First producer well anticipated online near end of 2026 supporting meaningful expected production growth in 2027.

George Maxwell, Vaalco’s Chief Executive Officer, commented, “We are pleased with the results of the ETSEM-3H development well, which was landed in an attic location within the SE Etame field, and is now on production at about 2,000 gross BOPD (1,140 BOPD net to Vaalco). This represents the final well in our successful Phase 3 drilling campaign, and the drilling rig has now been demobilized from the field. In Côte d’Ivoire, following the successful re-start of the Baobab field during the second quarter, we have now commenced the Phase 5 drilling campaign with batch-setting the top-hole sections of the new wells. The current plan for the Phase 5 drilling campaign consists of four producers, three water injectors and two workovers. We expect to have the first new producer online near the end of the year, with meaningful production increases expected in 2027. Our continued success and organic project pipeline support Vaalco’s strategic focus on growing production, reserves and value for our shareholders.”

About Vaalco

Vaalco Energy Inc. is an African-focused independent energy company with a diversified portfolio of production, development and exploration assets in Gabon, Egypt, Côte d’Ivoire and Equatorial Guinea. The Company combines cash-generative production assets with development and exploration opportunities supported by existing infrastructure and established operating histories. 

Since 2021, Vaalco has transformed from a single-asset producer into a multi-country African operator through disciplined acquisitions, portfolio optimization and operational delivery. Led by an experienced management team with a proven track record of value creation, Vaalco combines disciplined capital allocation, shareholder returns and a visible, self-funded pathway to significantly increase production from resources already within its portfolio.

Vaalco is headquartered in Houston and listed on the New York Stock Exchange and the Main Market of the London Stock Exchange under the symbol EGY. For further information, visit www.vaalco.com.

Vaalco’s Legal Entity Identifier (LEI) is 549300CFHFVIWB8M6T24.

For Further Information

Vaalco Energy, Inc. (General and Investor Enquiries) +00 1 713 543 3422
Website: www.vaalco.com
   
Al Petrie Advisors (US Investor Relations) +00 1 713 543 3422
Al Petrie / Chris Delange  
   
Camarco (Financial PR)  
Georgia Edmonds / Rebecca Waterworth (UK) +44 20 3757 4980
Rosie Driscoll (US) +00 1 771 241 3164
   

Forward Looking Statements

Information in this press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). Where a forward-looking statement expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis. All statements other than statements of historical fact may be forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “forecast,” “outlook,” “aim,” “target,” “will,” “could,” “should,” “may,” “likely,” “plan” and “probably” or similar words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements may include, but are not limited to, statements relating to (i) estimates of future drilling, production, sales and costs of acquiring crude oil, natural gas and natural gas liquids; (ii) expectations regarding future exploration and the development, growth and potential of Vaalco’s operations, project pipeline and investments, and schedule and anticipated benefits to be derived therefrom; (iii) expectations regarding future acquisitions, investments or divestitures; (iv) expectations of future dividends; (v) expectations of future balance sheet strength; and (vi) expectations of future equity and enterprise value.

Such forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to: risks relating to any unforeseen liabilities of Vaalco; the ability to generate cash flows that, along with cash on hand, will be sufficient to support operations and cash requirements; risks related to early production data not being indicative of long-term performance; and the risks described under the caption “Risk Factors” in Vaalco’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the SEC.

Any forward-looking statement made by Vaalco in this press release, is based only on information currently available to Vaalco and speaks only as of the date on which it is made. Except as may be required by applicable securities laws, Vaalco undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Inside Information

This announcement contains inside information as defined in Regulation (EU) No. 596/2014 on market abuse which is part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (“MAR”) and is made in accordance with the Company’s obligations under article 17 of MAR. The person responsible for arranging the release of this announcement on behalf of Vaalco is Matthew Powers, Corporate Secretary of Vaalco.

Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end

ZUG, Switzerland, October 7, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced that Riad Sherif, M.D., Chief Executive Officer of Oculis, will present at Eyecelerator @ AAO 2026 on October 8, 2026, and that the Company will sponsor the Neuro-Ophthalmology Subspecialty Day at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting on October 9, 2026, in New Orleans, Louisiana. 

At Eyecelerator @ AAO 2026, Dr. Sherif will present Licaminlimab, a novel topical anti-TNFα candidate being developed with a genotype-based precision medicine approach for TNFR1-mediated dry eye disease, in the PREDICT-1 registrational symptoms trial on track for topline readout around year-end.

Oculis will also partner with the Neuro-Ophthalmology Subspecialty Day, reflecting the Company’s commitment to advancing neuro-ophthalmology through scientific exchange, education, and collaboration with experts in research, clinical practice, and emerging technologies to improve care for patients with neuro-ophthalmic diseases. 

Riad Sherif, M.D., Chief Executive Officer of Oculis, said: “AAO provides a valuable opportunity to engage with the broader ophthalmology and neuro-ophthalmology communities and discuss how innovation can address persistent unmet needs in both fields. The upcoming topline results from PREDICT-1 have the potential to further advance our aim of bringing precision medicine to TNFR1-mediated dry eye disease, while the continued progress of Privosegtor reflects our commitment to transforming outcomes for patients facing neuro-ophthalmic diseases. Together, these programs illustrate Oculis’ strategy of pursuing highly differentiated therapies with the potential to redefine standards of care.”

Details of Oculis’ presentation at Eyecelerator @ AAO 2026 are as follows: 

Session: Anterior segment showcase
Date / Time: October 8, 1:24 PM CDT
Room: 243-245
Presenter: Riad Sherif, M.D., Chief Executive Officer

– Ends –

About Licaminlimab 

Licaminlimab is an anti-TNFα eye drop candidate being developed with a single chain antibody fragment (scFv) technology specifically developed to treat ocular inflammatory diseases. The dual anti-inflammatory and anti-necrotic mechanism of action of TNFα inhibition is well established in inflammatory disorders, where systemic use of TNFα inhibitors has led to marked improvements in disease management and treatment outcomes. In Phase 2 trials, Licaminlimab has shown a positive treatment effect on both the signs and symptoms of dry eye disease and has been well tolerated. In addition, a genetic biomarker has been identified that showed a more pronounced treatment effect with Licaminlimab in patients with a specific TNFR1 genotype. If approved, Licaminlimab has the potential to transform the treatment paradigm with a precision medicine approach. 

Licaminlimab is an investigational drug in a registrational trial and has not received regulatory approval for commercial use in any country. 

About Privosegtor 

Privosegtor, a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis (ON) and other neuro-ophthalmic and neuro-axonal diseases. Positive results from the ACUITY Phase 2 trial showed Privosegtor’s neuroprotective potential, as evidenced by improvements in visual function, corroborated by anatomical preservation of the retina, including GCIPL and RNFL layers, and reduced neurofilament levels in the blood after an acute episode of optic neuritis. Consistent results were observed in animal models of glaucoma, optic neuritis and multiple sclerosis, where Privosegtor preserved retinal ganglion cells and was associated with improvements in mobility in the multiple sclerosis model. 

Privosegtor has received Breakthrough Therapy designation from the U.S. Food and Drug Administration and Priority Medicines (PRIME) designation from the European Medicines Agency, as well as Orphan Drug designation from both agencies for ON. Privosegtor is currently being evaluated in Oculis’ PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program, which includes two registrational trials in ON and one registrational trial in non-arteritic anterior ischemic optic neuropathy. 

Privosegtor is an investigational drug and has not received regulatory approval for commercial use in any country. 

About Oculis 

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis and non-arteritic anterior ischemic optic neuropathy. Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neuro-axonal diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial and is being developed with a genotype-based approach for treating patients with dry eye disease. Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. 

For more information, please visit: www.oculis.com 

Contacts 

Oculis Contact 
Ms. Sylvia Cheung, CFO 
sylvia.cheung@oculis.com 

Investor Relations 
LifeSci Advisors 
Corey Davis, Ph.D. 
cdavis@lifesciadvisors.com 

Media Relations 
ICR Healthcare 
Amber Fennell / David Daley / Sean Leous 
oculis@icrhealthcare.com 

Cautionary Statement Regarding Forward-Looking Statements 

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, including the potential for Privosegtor to become the first neuroprotective therapy for optic neuritis and other neuro-ophthalmic and neuro-axonal diseases and the potential for Licaminlimab to transform the treatment paradigm in dry eye disease with a precision medicine approach; the initiation, enrollment, timing, progress and results of current and future clinical trials; Oculis’ research and development programs, regulatory and business strategy; Oculis’ future development plans; the timing or likelihood of regulatory filings and approvals; and statements about market opportunity, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and subject to risks, variability and contingencies, many of which are beyond Oculis’ control. Results from prior clinical trials may not be replicated in later clinical trials. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those expected and/or expressed or implied by such forward-looking statements, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. 

Elis announces the results of the conversion and exchange period
for its 2029 OCEANEs

Puteaux, October 7, 2026 – Elis (the “Company”) announces the results of the conversion/exchange period for its €380,000,000 2.25% bonds convertible into new shares and/or exchangeable for existing shares due September 22, 2029 (ISIN FR001400AFJ9) (the “Bonds”).

On September 11, 2026, the Company announced its decision to redeem all outstanding Bonds on October 13, 2026, pursuant to the first paragraph of Condition 1.10.1.3, “Early redemption at the Company’s option”, of the terms and conditions of the Bonds dated September 22, 2022 (the “Terms and Conditions”).

Capitalised terms that are not otherwise defined in this notice shall have the meanings given to them in the Terms and Conditions.

Bondholders had until October 2, 2026, to validly exercise their Conversion/Exchange Rights in accordance with the Terms and Conditions, at a conversion/exchange ratio of 6,256.8564 Elis shares per Bond.

A total of 3,767 Bonds were validly presented for conversion/exchange, representing 99.13% of the 3,800 Bonds outstanding on September 11, 2026. With a par value of €100,000 per Bond, this represents an aggregate nominal amount of €376,700,000.

Applying the Conversion/Exchange Ratio and the rounding provisions of the Terms and Conditions, these exercises will result in the delivery of a total of 23,569,556 Elis shares (ISIN FR0012435121), comprising 18,104,556 existing shares held in treasury and 5,465,000 new shares, representing in aggregate 9.89% of Elis’s share capital following the issuance of the new shares. The share capital of the Company now amounts to EUR 238,313,588, comprising 238,313,588 ordinary shares with a nominal value of EUR 1.00 each. The Company will use existing shares held following the completion of its share buyback program on July 9, 2026, thereby limiting the number of new shares to be issued. Settlement and delivery of the shares will be completed on October 7, 2026.

The remaining 33 Bonds, in respect of which conversion/exchange rights were not validly exercised, will be redeemed in cash on October 13, 2026, at a price of €100,129.45 per Bond, including €129.45 of accrued interest, representing an aggregate redemption amount of €3,304,271.85.

IMPORTANT NOTICE

This press release does not constitute an offer to sell, a solicitation of an offer to purchase, or an offer to purchase any securities of Elis in any jurisdiction.

Contacts

Nicolas Buron
Director of Investor Relations, Financing & Treasury
Phone: + 33 (0)1 75 49 98 30 – nicolas.buron@elis.com

Charline Lefaucheux
Investor Relations
Phone: + 33 (0)1 75 49 98 15 – charline.lefaucheux@elis.com

Attachment

First patient enrolled in cohort combining bexobrutideg with venetoclax

Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL

Strategy includes evaluation of bexobrutideg given in combination with venetoclax and selected antibodies in the Roche portfolio of B-cell malignancy therapies

BRISBANE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced that the first patient has been enrolled in the Phase 1b/2 NX-5948-203 study evaluating bexobrutideg, an investigational oral Bruton’s tyrosine kinase (BTK) degrader, in combination with venetoclax, a standard-of-care therapy for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

The study is being conducted under the global collaboration between Nurix and Roche and is designed to evaluate the safety, tolerability and clinical activity of bexobrutideg in combination with venetoclax, a BCL2 inhibitor. Data from the trial are expected to inform future registrational development strategies across lines of therapy in CLL, including evaluating bexobrutideg in combination with the anti-CD20 antibodies rituximab and obinutuzumab across multiple cohorts of patients with relapsed or refractory and previously untreated CLL, and potential expansion into other B-cell malignancies.

“The initiation of this study marks another important milestone in our effort to realize the full potential of bexobrutideg across B-cell malignancies,” said Arthur T. Sands, M.D., Ph.D., chief executive officer of Nurix. “Combination therapies are becoming increasingly important in the treatment of CLL, especially in earlier lines of therapy, and we believe bexobrutideg’s differentiated mechanism of action, robust single-agent activity and favorable tolerability make it an attractive partner for combination approaches to deliver deep, durable responses with fixed-duration therapy.”

About Bexobrutideg (NX-5948)
Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant, highly selective small-molecule degrader of Bruton’s tyrosine kinase (BTK) being developed by Nurix and Roche as a potential best-in-class therapy across oncology, immunology and neurology.

​​​Bexobrutideg is currently being evaluated in a broad clinical development program in patients with chronic lymphocytic leukemia (CLL), including the DAYBreak CLL-201 clinical trial (NCT07221500), a pivotal single-arm Phase 2 study in patients with relapsed/refractory CLL previously treated with covalent and noncovalent BTKi and a BCL2i; the DAYBreak CLL-306 clinical trial (NCT07516093), a randomized Phase 3 trial comparing bexobrutideg to pirtobrutinib in patients with relapsed/refractory CLL previously treated with a covalent BTKi; the NX-5948-203 Phase 1b/2 clinical trial (NCT07520006), assessing the combination of bexobrutideg with venetoclax in patients with relapsed/refractory CLL and potentially treatment-naïve CLL; and the NX-5948-301 Phase 1a/1b clinical trial (NCT05131022) in patients with relapsed/refractory B-cell malignancies. Additional information about these clinical trials can be found at clinicaltrials.gov.

About Nurix Therapeutics
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, a new frontier in drug discovery aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s clinical-stage oncology pipeline includes bexobrutideg, a degrader of BTK being co-developed with Roche, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix’s autoimmune disease pipeline includes bexobrutideg in collaboration with Roche and clinical-stage degraders of IRAK4 in collaboration with Gilead and STAT6 in collaboration with Sanofi. Nurix is also advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates in its wholly owned preclinical pipeline and under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in Brisbane, California. For additional information, visit www.nurixtx.com.

Forward-Looking Statements
This press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this press release, the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “outlook,” “plan,” “predict,” “should,” “will,” and similar expressions and their variants, as they relate to Nurix, may identify forward-looking statements. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding Nurix’s plans for the development of bexobrutideg and the potential of bexobrutideg to serve as a foundational component of future combination regimens. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions. Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) whether Nurix and Roche will be able to successfully conduct and complete clinical development of bexobrutideg pursuant to the Nurix-Roche collaboration; (ii) the unexpected emergence of adverse events or other undesirable side effects during clinical development; (iii) whether Nurix will have adequate resources to fund its obligations under the Nurix-Roche collaboration; (iv) whether the parties will be able to successfully co-commercialize bexobrutideg in the United States; and (v) other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the fiscal period ended May 31, 2026, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.

Contacts:
Media & Investors
Kris Fortner
Nurix Therapeutics, Inc.
kfortner@nurixtx.com

SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares of common stock, pre-funded warrants to purchase 400,000 shares of common stock and $500 million aggregate principal amount of 1.50% convertible senior notes due 2032 (the “notes”). The shares of common stock are being sold at a public offering price of $64.00 per share, and the pre-funded warrants are being sold at a public offering price of $63.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The shares of common stock, pre-funded warrants and notes to be sold in the offerings are being offered by Vaxcyte. Vaxcyte has granted the underwriters of the common stock and pre-funded warrant offering a 30-day option to purchase up to an additional 1,171,875 shares of its common stock at the public offering price per share, and has granted the underwriters of the note offering a 30-day option to purchase up to an additional $75 million aggregate principal amount of notes at the public offering price, solely to cover over-allotments, in each case less underwriting discounts and commissions.

The aggregate gross proceeds to Vaxcyte from the common stock and pre-funded warrants offering are expected to be approximately $500 million and the aggregate gross proceeds to Vaxcyte from the notes offering are expected to be $500 million, in each case before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants and assuming no exercise of the underwriters’ options.

Vaxcyte intends to use the net proceeds from the offerings to fund (i) clinical development of the VAX-31 adult and pediatric programs, including (a) for the ongoing VAX-31 adult Phase 3 program, the trial evaluating concomitant administration with a seasonal influenza vaccine (OPUS-2, enrolled), the trial in adults who have previously received a pneumococcal vaccine (OPUS-3, enrolled) and the planned manufacturing consistency study, and the anticipated topline safety, tolerability and immunogenicity data announcements from such studies, and (b) for the VAX-31 infant Phase 2 dose-finding study (enrolled), the anticipated topline data announcement(s) from the primary three-dose immunization series and booster dose; (ii) manufacturing scale-up, processes and supply to support our clinical studies and the potential commercial launches of our PCV programs, including (a) to establish additional manufacturing capacity to meet potential incremental supply requirements for the global adult and pediatric populations following the potential initial commercial launch of VAX-31 in adults in the United States and (b) to build inventory levels in advance of such potential commercial launch; (iii) medical affairs, commercial and systems-related investments to prepare for and execute the anticipated U.S. launch of VAX-31 in adults; (iv) ongoing research and development of our other early-stage pipeline vaccine candidates; and (v) general corporate purposes, including working capital, operating expenses and capital expenditures, as well as potential expansion of Vaxcyte’s research pipeline.

The completion of the common stock and pre-funded warrant offering is not contingent on the completion of the note offering, and the completion of the note offering is not contingent on the completion of the common stock and pre-funded warrant offering.

The offerings are expected to close on October 9, 2026, subject to the satisfaction of customary closing conditions.

Jefferies, Leerink Partners, BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC and Guggenheim Securities are acting as joint book-running managers for the common stock and pre-funded warrant offering. Mizuho is acting as bookrunner and BTIG is acting as lead manager for the common stock and pre-funded warrant offering.

Jefferies, Leerink Partners, BofA Securities, Goldman Sachs & Co. LLC and Evercore ISI are acting as joint book-running managers for the note offering. Guggenheim Securities and Mizuho are acting as bookrunners and Needham & Company is acting as lead manager for the note offering.

J. Wood Capital Advisors is acting as financial advisor to Vaxcyte in connection with the note offering.

The notes will be senior, unsecured obligations of Vaxcyte and will accrue interest at a rate of 1.50% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, beginning on April 15, 2027. The notes will mature on October 15, 2032, unless earlier repurchased, redeemed or converted. Before July 15, 2032, noteholders will have the right to convert their notes only upon the occurrence of certain events. From and after July 15, 2032, noteholders may convert their notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Vaxcyte will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at Vaxcyte’s election. The initial conversion rate is 11.1607 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $89.60 per share of common stock. The initial conversion price represents a premium of approximately 40.0% over the public offering price per share of common stock in the common stock offering. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.

The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Vaxcyte’s option at any time, and from time to time, on or after October 22, 2029 and on or before the 20th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Vaxcyte’s common stock exceeds 130% of the conversion price for a specified period of time. The notes will also be redeemable, in whole and not in part, for cash at Vaxcyte’s election at any time if the principal amount of the notes then outstanding is less than 10% of the aggregate principal amount of the notes issued in this offering (including any additional notes issued pursuant to any exercise of the underwriters’ option to purchase additional notes). The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

If a “fundamental change” (as defined in the indenture for the notes) occurs, then, subject to a limited exception, noteholders may require Vaxcyte to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.

A shelf registration statement relating to the offered securities was filed with the Securities and Exchange Commission (SEC) and was automatically effective upon filing on May 24, 2024. A preliminary prospectus supplement and accompanying prospectus relating to each offering has been filed, and a final prospectus supplement and accompanying prospectus relating to each offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to each offering may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by email at syndicate@leerink.com or by phone at (800) 808-7525, ext. 6105.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Vaxcyte

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, has generated positive Phase 2 clinical results in both adults and infants and is designed to cover more serotypes than any PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages Vaxcyte’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in Vaxcyte’s PCV franchise.

VAX-A1 is a prophylactic vaccine candidate designed to provide broad, strain-independent protection against disease caused by Group A Strep and is currently being evaluated in a Phase 1 clinical study in adults. Group A Strep remains a significant global cause of morbidity and mortality across both adult and pediatric populations and is a leading driver of antibiotic use, underscoring the substantial public health burden.

Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, Vaxcyte’s system for producing difficult-to-make proteins and antigens is intended to develop and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-GI, a vaccine candidate designed to prevent Shigella.

Forward-Looking Statements

This press release contains forward-looking statements regarding Vaxcyte, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the completion, timing and expected closing of the offerings, the expected amount of the gross proceeds of the offerings and the intended use of the net proceeds therefrom. Words such as “expects,” “intends,” “intended,” “designed,” “aim,” “will” and “may” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements represent Vaxcyte’s current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are market and other conditions, the satisfaction of the closing conditions related to the offerings, risks described under the caption “Risk Factors” in the preliminary prospectus supplements (and, when available, the final prospectus supplements) for the offerings, risks relating to Vaxcyte’s business, and the other risks described more fully in Vaxcyte’s filings with the Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026 or in other documents Vaxcyte subsequently files with or furnishes to the SEC. Vaxcyte may not consummate the offerings described in this press release and, if the offerings are consummated, cannot provide any assurances regarding its ability to effectively apply the net proceeds as described above. You should not place undue reliance on these forward-looking statements. The forward-looking statements included in this press release speak only as of the date of this press release, and Vaxcyte does not undertake to update the statements included in this press release for subsequent developments, except as may be required by law.

Contacts:

Patrick Ryan, Executive Director, Corporate Affairs
Vaxcyte, Inc.
415-606-5135
media@vaxcyte.com

Jeff Macdonald, Executive Director, Investor Relations
Vaxcyte, Inc.
917-371-0940
investors@vaxcyte.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.